

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

PRO PHARMACEUTICALS INC
Form POS AM
April 23, 2002

Registration No. 333-74604

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

POST-EFFECTIVE AMENDMENT NO. 1 TO
FORM SB-2

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

PRO-PHARMACEUTICALS, INC.
(Name of Small Business Issuer in its Charter)

Nevada	8731	04-3562325
(State or other jurisdiction of incorporation or organization)	(Primary Standard Industrial Classification Code Number)	(I.R.S. Employer Identification No.)

189 Wells Avenue, Suite 200
Newton, Massachusetts 02459
(617) 559-0033
(Address and Telephone Number of
Principal Executive Offices)

David Platt, Ph.D.
President and Chief Executive Officer
Pro-Pharmaceuticals, Inc.
189 Wells Avenue, Suite 200
Newton, Massachusetts 02459
(617) 559-0033
(Name, Address and Telephone Number
of Agent for Service)

with copies to:

Jonathan C. Guest, Esq.
Perkins, Smith & Cohen, LLP
One Beacon Street
Boston, Massachusetts 02108
(617) 854-4000

Approximate date of re-commencement of proposed sale to the public: As soon as possible after this Post-Effective No. 1 to the Form SB-2 Registration Statement is declared effective.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box [X]

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering []

If this Form is a post-effective amendment filed pursuant to Rule 462(c)

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering

If delivery of the prospectus is expected to be made pursuant to Rule 434, check the following box

CALCULATION OF REGISTRATION FEE

Title of Each Class of Securities to be Registered	Number of Units/Shares to be Registered (1)	Proposed Maximum Offering Price per Unit (2)	Proposed Maximum Aggregate Offering Price (3)	Re
Common Stock, \$.001 par value	2,650,462	\$3.50	\$9,276,617	

- (1) Total represents 1,428,572 shares of Common Stock to be offered by the Registrant and up to 1,221,890 already issued shares of the Common Stock of the Registrant to be offered by selling security holders of the Registrant. In the event of a stock split, stock dividend or similar transaction involving the Common Stock of the Registrant, in order to prevent dilution, the number of shares registered shall be automatically increased to cover additional shares in accordance with Rule 416(a) under the Securities Act.
- (2) Represents proposed maximum price per share of Common Stock to be offered by the Registrant.
- (3) Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(o) under the Securities Act, based on proposed maximum offering price per share of Common Stock to be offered by the Registrant.

The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until this Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

PRO-PHARMACEUTICALS, INC.

2,650,462 Shares of Common Stock
\$.001 par value

Of the 2,650,462 shares of Pro-Pharmaceuticals common stock offered by this prospectus, 1,428,572 shares are being sold by Pro-Pharmaceuticals on a "best efforts" basis. The other 1,221,890 shares may be offered and sold, from time to time, by the selling security holders identified in this prospectus. We will not receive any of the proceeds from the sale of shares by the selling security holders.

There is currently no market for our common stock. We anticipate that we

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

will retain a market maker to apply for trading of our common stock on the Over-the-Counter Bulletin Board following effectiveness of this registration statement.

INVESTING IN OUR COMMON STOCK INVOLVES A HIGH DEGREE OF RISK. SEE "RISK FACTORS" BEGINNING ON PAGE 2 TO READ ABOUT CERTAIN RISKS YOU SHOULD CONSIDER BEFORE BUYING SHARES OF OUR COMMON STOCK.

NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

	Price to Public	Placement Fees (1)	Proceeds to Company (2)
Per Share	\$3.50	\$0.2975	\$3.2025
Total (3)	\$5,000,000	\$425,000	\$4,575,000

- (1) The 1,428,572 shares offered by Pro-Pharmaceuticals are being offered principally to selected institutional and accredited investors. We have retained Atlas Capital Services, LLC, to act, on a best efforts basis, as our placement agent in connection with the arrangement of this transaction. We have agreed, among other things, to pay Atlas Capital a fee, including issuance of warrants, in connection with the arrangement of this financing and to indemnify Atlas Capital against certain liabilities, including liabilities under the Securities Act of 1933. See "Plan of Distribution."
- (2) Before deducting expenses payable by Pro-Pharmaceuticals estimated at \$120,000. We will not receive any proceeds from the sale of shares by the selling security holders.
- (3) We cannot assure you that any of the shares of common stock offered by this prospectus will be sold. Since the offering is made on a best efforts basis, there is no firm commitment by Atlas Capital to purchase or sell any of the shares of common stock. There is no minimum number of shares of common stock required to be sold by us, and no arrangements have been made to escrow any proceeds of the offering. Therefore, we may sell less than all of the shares of common stock offered hereby, which may significantly reduce the amount of proceeds that we receive. We anticipate concluding our offering of common stock on June 11, 2002.

The date of this Prospectus is April ____, 2002.

Legend for Residents of all States:

The securities offered hereby have not been registered under the securities laws of any state and are being offered and sold in reliance on exemptions from the registration requirements of such laws. The securities may be subject to restrictions on transferability and resale under state securities laws and may not be transferred or resold except as permitted under such laws pursuant to registration or exemption therefrom. This prospectus, as accessible electronically as an EDGAR filing on the Securities and Exchange Commission website or other commercial websites, does not constitute an offer or solicitation in any state (including California and Michigan) or jurisdiction in which such offer or solicitation is not authorized.

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

TABLE OF CONTENTS

PROSPECTUS SUMMARY.....	
THE OFFERING.....	
RISK FACTORS.....	
We are at an early stage of development without operating history.....	
We have incurred net losses to date and depend on outside capital.....	
We may not be able to sell all of the shares we are currently offering.....	
Our product candidates will be based on novel technologies.....	
We must successfully develop products in order to generate revenue.....	
We will need regulatory approvals to commercialize our products.....	
Our product candidates may not be successfully commercialized.....	
We have no experience in clinical trials.....	
Our competitive position depends on protection of our intellectual property.....	
Our products could infringe on the intellectual property rights of others.....	
Our lack of operating experience may cause us difficulty in managing our growth.....	
Our business is subject to technological obsolescence.....	
We face intense competition in the biotechnology and pharmaceutical industries.....	
We will depend on third parties to manufacture and market our products.....	
We depend on key personnel to develop our products and pursue collaborations.....	
A former employer of our President alleged in early 2001 a violation of a non-competition covenant expiring on June 29, 2002.....	
We face potential difficulties in obtaining product liability and related insurance.....	
Health care cost containment initiatives may limit our returns.....	
Environmental regulations may affect our manufacturers and other contractors.....	
Our ability to conduct animal testing could be limited in the future.....	
Stock prices for biopharmaceutical and biotechnology companies are volatile.....	
Our stock is not listed on any exchange or quoted on Nasdaq.....	
If our stock is a "penny stock," your ability to trade our shares could be adversely affected.....	
Purchasers of stock may be subject to substantial dilution.....	
Four principal stockholders own enough shares to control the company.....	
FORWARD-LOOKING STATEMENTS.....	
USE OF PROCEEDS.....	
MARKET FOR OUR COMMON STOCK AND RELATED STOCKHOLDER MATTERS.....	
PLAN OF OPERATION.....	
CAPITALIZATION.....	
SELECTED FINANCIAL DATA.....	
BUSINESS.....	
MANAGEMENT.....	
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT.....	
DILUTION.....	
SELLING SECURITY HOLDERS.....	
PLAN OF DISTRIBUTION.....	
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.....	
DESCRIPTION OF CAPITAL STOCK.....	
LEGAL MATTERS.....	
EXPERTS.....	
FINANCIAL STATEMENTS.....	

NOTE: The Registration Statement on Form SB-2 of the Registrant, as filed with the Commission on December 5, 2001, is being amended by this Amendment No. 1 primarily for the following reasons: (1) to reflect restatement of the audited

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

financial statements of Pro-Pharmaceuticals, Inc., a Massachusetts corporation and predecessor to the Registrant, for the period from inception (July 10, 2000) through December 31, 2000; (2) to include the Registrant's audited financial statements for the year ended December 31, 2001; and (3) to update disclosure since the Registration Statement as originally filed was declared effective on December 12, 2001.

PROSPECTUS SUMMARY

About This Prospectus

This prospectus is part of a registration statement we filed with the U.S. Securities and Exchange Commission. You should rely only on the information provided in this prospectus. Neither we, Atlas Capital nor the selling security holders listed in this prospectus have authorized anyone to provide you with information different from that contained in this prospectus. Pro-Pharmaceuticals and the selling security holders are offering to sell, and seeking offers to buy, shares of common stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of common stock. Applicable SEC rules may require us to update this prospectus in the future. This preliminary prospectus is subject to completion prior to this offering.

About Pro-Pharmaceuticals, Inc.

We are currently in the development stage and have not yet generated any operating revenues. Since the formation in July 2000 of our predecessor, Pro-Pharmaceuticals, Inc., a Massachusetts corporation, we have been engaged in research and development activities in connection with identifying and developing a technology that will reduce toxicity and improve the efficacy of currently-used drug therapies, including cancer chemotherapies, by combining the drugs with a number of carbohydrate compounds. Our preliminary studies have identified certain mannans, a group of polysaccharides, that could be utilized as a potential drug delivery system. Polysaccharides are molecules consisting of one or more types of sugars. In the case of mannans, the principal component is the sugar mannose, which is similar to glucose. We believe that a mannan having a suitable chemical structure and composition, when attached to or combined with the active agent of a chemotherapy drug, would increase cellular membrane fluidity and permeability, thereby assisting delivery of the drug. We are currently conducting preclinical animal experiments.

Corporate Information

We were incorporated as "DTR-Med Pharma Corp." under Nevada law in January 2001 for the purpose of acquiring all the outstanding stock of our predecessor, Pro-Pharmaceuticals, Inc., which was a Massachusetts corporation engaged in a business we desired to acquire. From our incorporation until just before the acquisition, we were a wholly-owned subsidiary of Developed Technology Resource, Inc., a Minnesota corporation whose common stock is publicly traded on the Over-the-Counter Bulletin Board. In exchange for 1,221,890 shares of our common stock, Developed Technology transferred to us contractual rights that are described below under "Business -- Business of Pro-Pharmaceuticals -- Cancer Detection Technology." As part of that process, Developed Technology distributed its holdings of our common stock to its shareholders of

record as of May 7, 2001. In anticipation of the acquisition of the Massachusetts company, we changed our name to "Pro-Pharmaceuticals, Inc."

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

On May 15, 2001, we acquired all of the outstanding common stock of the Massachusetts corporation. We acquired these shares in exchange for 12,354,670 shares of our common stock. As a result, that corporation became our wholly owned subsidiary, and its shareholders through an exchange owned approximately 91% of the outstanding shares of our common stock, with the Developed Technology shareholders owning the remaining 9%. See "Security Ownership of Certain Beneficial Owners and Management" for information about the ownership of our common stock. After the acquisition, we merged with the Massachusetts corporation and are the surviving corporation in the merger.

As required by the stock exchange agreement that effected the acquisition, we registered our common stock under the Securities Exchange Act of 1934 by filing a Registration Statement on Form 10-SB with the Securities and Exchange Commission that became effective on August 13, 2001. Our articles of organization provide that our common stock may not be sold without our approval until the 90th day after the date our common stock is registered. Accordingly, our common stock became eligible for transfer, subject to applicable federal and state securities law requirements, as of November 11, 2001. We anticipate that we will retain a market maker to apply for trading of our common stock on the Over-the-Counter Bulletin Board following effectiveness of this registration statement.

Our address is 189 Wells Avenue, Suite 200, Newton, Massachusetts 02459. Our telephone number is (617) 559-0033, fax number is (617) 928-3450, e-mail address is foley@pro-pharmaceuticals.com, and our website address is www.pro-pharmaceuticals.com.

THE OFFERING

Common stock offered by us:	1,428,572 shares
Common stock offered by the selling security holders:	1,221,890 shares
Common stock currently outstanding (as of April 8, 2002):	15,524,410 shares
Common stock to be outstanding after the offering assuming sale of all common stock offered by us:	16,952,982 shares

Use of Proceeds:

We intend to use the net proceeds of research and development activities, experiments, and for other general o

We will not receive proceeds from the selling security holders.

RISK FACTORS

An investment in our common stock involves a high degree of risk. You should carefully consider the risks described below and the other information contained in this prospectus before deciding to invest in our common stock. The risks described below are not the only ones facing our company. Additional risks not presently known to us or which we currently consider immaterial may also adversely affect our business. We have attempted to identify the major factors

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

under the heading "Risk Factors" that could cause differences between actual and planned or expected results, but we cannot assure you that we have identified all of those factors. If any of the following risks actually happen, our business, financial condition and operating results could be materially adversely affected. In this case, no market may develop for our common stock or, if there is a market, the trading price of our common stock could decline, and you could lose part or all of your investment.

We are at an early stage of development without operating history.

We are a development-stage venture without operating history. Our future revenues and profits are uncertain. We were incorporated in January 2001. Our predecessor, Pro-Pharmaceuticals (Massachusetts) was incorporated in July 2000. We have not generated any revenues to date. Though we have prepared and tested several carbohydrate-based formulations in preclinical studies, we have not prepared formulations of any therapeutic product for testing, and we have not commenced any clinical trials. We have no therapeutic products available for sale, and none are expected to be commercially available for several years, if at all. Our research activities may not lead to the development of any commercially viable products. We may never generate revenue or become profitable, even if we are able to commercialize any products. If we are unable to generate revenues or profits, you might not be able to realize returns on your investment in our company. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.

We have incurred net losses to date and depend on outside capital.

Our predecessor, Pro-Pharmaceuticals (Massachusetts) had incurred net operating losses since its incorporation in July 2000. Our accumulated deficit as of December 31, 2001 was approximately \$4,158,000 which includes approximately \$1,960,000 of various non-cash charges related to certain equity transactions. We will need to conduct significant research, development, testing and regulatory compliance activities that, together with projected general and administrative expenses, we expect will result in substantial increasing operating losses for at least the next several years. Accordingly, we will not be generating our own capital and will remain dependent on outside sources of financing during that time.

As of December 31, 2001, we had approximately \$1,491,000 in cash and cash equivalents. We have budgeted expenditures for the twelve-month period ending December 31, 2002 of approximately \$5,600,000. We attempted to fund these expenditures through proceeds of a private placement that we began in May 2001. We abandoned the private placement as of December 3, 2001, and terminated all offering activity on or before that date. We raised \$2,237,500 prior to termination.

On December 13, 2001, we commenced a public offering of 1,428,572 shares of our common stock, at a price to the public of \$3.50 per share, pursuant to this registration statement on Form SB-2 as originally filed and declared effective by the SEC on December 12, 2001. We anticipated concluding the offering on February 11, 2002 but extended the offering until June 11, 2002. As of April 8, 2002, we had sold but not issued approximately 50,570 shares pursuant to our public offering.

We will require substantial funds to: (1) continue our research and development programs, (2) acquire technologies by license or purchase, and (3) conduct preclinical studies and clinical trials. We may need to raise additional capital to fund our operations repeatedly. We may raise such capital through public or private equity financings, partnerships, debt financings, bank borrowings, or other sources. Our capital requirements will depend upon numerous factors, including the following:

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

- o the establishment of collaborations

3

- o the development of competing technologies or products
- o changing market conditions
- o the cost of protecting our intellectual property rights
- o the progress of our research and development programs, the progress of our collaborations and receipt of any option/license, milestone and royalty payments resulting from those collaborations
- o technology acquisition opportunities

Additional funding may not be available on favorable terms or at all. If adequate funds are not otherwise available, we may curtail operations significantly. To obtain additional funding, we may need to enter into arrangements that require us to relinquish rights to certain technologies, products and/or potential markets. To the extent that additional capital is raised through the sale of equity, or securities convertible into equity, you may experience dilution of your proportionate ownership of the company.

We may not be able to sell all of the shares we are currently offering.

Upon this registration becoming effective, we plan to offer and sell to institutional and accredited investors identified by Atlas Capital Services, LLC, as our placement agent, shares of our common stock for proceeds of up to \$5,000,000 before expenses. Please see "Plan of Operation -- Liquidity and Capital Resources" for further discussion of our present financing plans. If we sell all of the 1,428,572 shares through Atlas Capital that we are offering by this prospectus, our estimated proceeds would be \$4,455,000 after deducting the estimated placement fee of \$425,000 and offering expenses including \$20,000 as a placement agent due diligence fee and estimated \$100,000 for accounting, legal and printing expenses. We cannot assure you that we will succeed in selling any or all of the shares of common stock we are currently offering. We have not fixed a minimum number of shares of common stock to be sold by us in this offering. Therefore, we may sell less than all of the shares of common stock offered by this prospectus, which may significantly reduce the amount of proceeds we receive. In any case, we will have to raise additional funds to continue the development of our technologies and complete the commercialization of products, if any, resulting from our technologies.

Our product candidates will be based on novel technologies.

Our product candidates will be based upon novel technologies that we plan to use to apply to drugs currently used in the treatment of cancer and other diseases. These technologies have not been proven. Carbohydrates are difficult to synthesize, and we may not be able to synthesize carbohydrates that would be usable as delivery vehicles for the anti-cancer drugs we plan to work with. Furthermore, as is often the case, preclinical results in animal studies may not predict outcomes in human clinical trials. Our product candidates may not be proven safe or effective. If this technology does not work, our product candidates may not develop into commercial products.

We must successfully develop products in order to generate revenue.

Our product candidates are still in research and preclinical development, which means that they have not yet been tested on humans. We will need to commit

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

significant time and resources to develop these and additional product candidates. We are dependent on the successful completion

4

of clinical trials and obtaining regulatory approval in order to generate revenues. The failure to generate such revenues may preclude us from continuing our research and development of these and other product candidates.

We have no product candidates in clinical trials, and we do not know when, if ever, we will have a candidate and commence clinical trials. Clinical trials are expensive, time-consuming and may not be successful. They involve the testing of potential therapeutic agents, or effective treatments, in humans in three phases (phases I, II, and III) to determine the safety and efficacy of the product candidates necessary for an approved drug. Many products in human clinical trials fail to demonstrate the desired safety and efficacy characteristics. Even if our products progress successfully through initial human testing, they may fail in later stages of development. A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials, even after reporting promising results in earlier trials. In addition, data obtained from clinical trials are susceptible to varying interpretations. Government regulators and our collaborators may not agree with our interpretation of our future clinical trial results. The clinical trials of any of our future product candidates may not be successful.

We will need regulatory approvals to commercialize our products.

We do not have any product approved for sale in the U.S. or any foreign market. We must obtain approval from the FDA in order to sell our products in the U.S. and from foreign regulatory authorities in order to sell our drug products in other countries. We have not yet submitted any application for approval to the FDA. Once an application is submitted, the FDA could reject the application or require us to conduct additional clinical or other studies as part of the regulatory review process. Delays in obtaining or failure to obtain FDA approvals would prevent or delay the commercialization of our products, which would prevent, defer or decrease our receipt of revenues.

The regulatory review and approval process is lengthy, expensive and uncertain. Extensive preclinical and clinical data and supporting information must be submitted to the FDA for each indication for each product candidate in order to secure FDA approval. We have no experience in obtaining such approvals, and cannot be certain when we will receive these regulatory approvals, if ever.

In addition to initial regulatory approval, our product candidates will be subject to extensive and rigorous ongoing domestic and foreign government regulation, as we discuss in more detail in "Business -- Business of Pro-Pharmaceuticals -- Government Regulation," below. Any approvals, once obtained, may be withdrawn if compliance with regulatory requirements is not maintained or safety problems are identified. Failure to comply with these requirements may subject us to stringent penalties.

Our product candidates may not be successfully commercialized.

Even if our product candidates are successful in clinical trials, they may not be successfully commercialized. All of our compounds currently are in research or development, and none has been submitted for marketing approval. There can be no assurance that any of our compounds will enter human clinical trials on a timely basis, if at all, or that we will develop any product candidates suitable for commercialization. Prior to commercialization, each product candidate will require significant additional research, development and

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

preclinical testing and extensive clinical investigation before submission of any regulatory application for marketing approval. Potential products that appear to be promising at early stages of development may not reach the market for a number of reasons. Potential products may:

5

- o be found ineffective or cause harmful side effects during preclinical testing or clinical trials
- o fail to receive necessary regulatory approvals
- o be difficult to manufacture on a large scale
- o be uneconomical to produce
- o fail to achieve market acceptance
- o be precluded from commercialization by proprietary rights of third parties

We cannot assure you that we will undertake any product development efforts, either alone or with collaborative partners. If we do undertake product development efforts, we cannot assure you that any of those efforts will be successfully completed, that required regulatory approvals will be obtained or that any products, if introduced, will be successfully marketed or achieve customer acceptance.

We have no experience in clinical trials.

We have no experience in conducting clinical trials and will be dependent on others to conduct our clinical trials. We intend to rely on academic institutions or clinical research organizations to conduct, supervise or monitor some or all aspects of clinical trials involving our products. In addition, certain clinical trials for our products may be conducted by government-sponsored agencies and consequently will be dependent on governmental participation and funding. We will have less control over the timing and other aspects of these clinical trials than if we conducted them entirely on our own. We cannot assure you that these trials will commence or be completed as we expect or that they will be conducted successfully. Failure to commence or complete, or delays in, any of our planned clinical trials could delay or prevent the commercialization of our products and harm our business. The actual timing of clinical trials can vary dramatically due to factors such as delays, scheduling conflicts with participating clinicians and clinical institutions and the rate of patient accruals. We cannot assure you that clinical trials involving our product candidates will commence or be completed as forecasted.

Our competitive position depends on protection of our intellectual property.

Development and protection of our intellectual property are critical to our business. If we do not adequately protect our intellectual property, competitors may be able to practice our technologies. Our success depends in part on our ability to:

- o obtain patent protection for our products or processes both in the United States and other countries
- o protect trade secrets
- o prevent others from infringing on our proprietary rights

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

While we believe that linking our carbohydrate polymers to existing drugs will yield patentable subject matter, to date we have only two pending patent applications, as well as a provisional patent application as discussed below under "Business -- Business of Pro-Pharmaceuticals -- Patents and Proprietary Rights." We do not believe that our carbohydrate-drug conjugates will infringe any third-party patents covering the underlying drug. However, there can

6

be no assurance that we will receive a patent for our carbohydrate-drug conjugates. In addition, we must meet further filing deadlines in the case of our provisional patent applications if we are to retain the filing, or priority, dates for those applications, as discussed below under "Business -- Business of Pro-Pharmaceuticals -- Patents and Proprietary Rights."

Since patent applications in the United States are maintained in secrecy until patents are issued, and since publication of discoveries in the scientific or patent literature often lag behind actual discoveries, we cannot be certain that we are the first to make the inventions to be covered by the patent applications we intend to file. The patent position of biopharmaceutical firms generally is highly uncertain and involves complex legal and factual questions. The U.S. Patent and Trademark Office has not established a consistent policy regarding the breadth of claims that it will allow in biotechnology patents. If it allows broad claims, the number and cost of patent interference proceedings in the U.S. and the risk of infringement litigation may increase. If it allows narrow claims, the risk of infringement may decrease, but the value of our rights under our patents, licenses and patent applications may also decrease.

We cannot assure you that patent applications in which we have rights will ever issue as patents or that the claims of any issued patents will afford meaningful protection for our technologies or products. In addition, patents issued to us or our licensors may be challenged and subsequently narrowed, invalidated or circumvented. Litigation, interference proceedings or other governmental proceedings that we may become involved in with respect to our proprietary technologies or the proprietary technology of others could result in substantial cost to us. Patent litigation is widespread in the biotechnology industry, and any patent litigation could harm our business. Costly litigation might be necessary to protect our patent position or to determine the scope and validity of third-party proprietary rights, and we may not have the required resources to pursue such litigation or to protect our patent rights. An adverse outcome in litigation with respect to the validity of any of our patents could subject us to significant liabilities to third parties, require disputed rights to be licensed from third parties or require us to cease using a product or technology.

Although we require our scientific and technical employees and consultants to enter into broad assignment of inventions agreements, we have not required Dr. Platt to do so. He has, however, assigned all his patents and patent applications of inventions related to our company's business. We also rely upon trade secrets, proprietary know-how and continuing technological innovation to remain competitive. Third parties may independently develop such know-how or otherwise obtain access to our technology. While our employees, consultants and corporate partners with access to proprietary information generally will be required to enter into confidentiality agreements, these agreements may not be honored.

Patents issued to third parties may cover our products as ultimately developed. We may need to acquire licenses to these patents or challenge the validity of these patents. We may not be able to license any patent rights on

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

acceptable terms or successfully challenge such patents. The need to do so will depend on the scope and validity of these patents and ultimately on the final design or formulation of the products and services that we develop. We may not be able to meet our obligations under those licenses that we do enter into. If we enter into a license agreement for intellectual property underlying any of our products, and that license were to be terminated, we may lose our right to market and sell any products based on the licensed technology.

Our products could infringe on the intellectual property rights of others.

Although we attempt to monitor the patent filings of our competitors in an effort to guide the design and development of our products to avoid infringement, third parties may challenge the patents that have been issued or licensed to us. We may have to pay substantial damages, possibly

7

including treble damages, for past infringement if it is ultimately determined that our products infringe a third party's patents. Further, we may be prohibited from selling our products before we obtain a license, which, if available at all, may require us to pay substantial royalties. Even if infringement claims against us are without merit, defending a lawsuit takes significant time, may be expensive and may divert management attention from other business concerns.

Our lack of operating experience may cause us difficulty in managing our growth.

We have no experience in manufacturing or procuring products in commercial quantities and conducting other later-stage phases of the regulatory approval process, or in selling pharmaceutical products, and we have only limited experience in negotiating, establishing and maintaining strategic relationships. We have no experience with respect to the launch of a commercial product. Our ability to manage our growth, if any, will require us to improve and expand our management and our operational and financial systems and controls. If our management is unable to manage growth effectively, our business and financial condition would be materially harmed. In addition, if rapid growth occurs, it may strain our operational, managerial and financial resources.

Our business is subject to technological obsolescence.

Biotechnology and related pharmaceutical technology have undergone and are subject to rapid and significant change. We expect that the technologies associated with biotechnology research and development will continue to develop rapidly. Our future will depend in large part on our ability to maintain a competitive position with respect to these technologies. Any compounds, products or processes that we develop may become obsolete before we recover any expenses incurred in connection with developing these products.

We face intense competition in the biotechnology and pharmaceutical industries.

The biotechnology and pharmaceutical industries are intensely competitive. We have numerous competitors in the United States and elsewhere. Our competitors include major, multinational pharmaceutical and chemical companies, specialized biotechnology firms and universities and other research institutions. Many of these competitors have greater financial and other resources, larger research and development staffs and more effective marketing and manufacturing organizations, than we do. In addition, academic and government institutions have become increasingly aware of the commercial value of their research findings. These institutions are now more likely to enter into exclusive licensing agreements with commercial enterprises, including our competitors, to

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

market commercial products. Smaller companies may also prove to be significant competitors, particularly through collaborative arrangements with large pharmaceutical and established biotechnology companies. Many of these competitors have significant products that have been approved or are in development and operate large, well-funded research and development programs.

Our competitors may succeed in developing or licensing technologies and products that are more effective or less costly than any we are developing. Our competitors may succeed in obtaining FDA or other regulatory approvals for product candidates before we do. In particular, we face direct competition from many companies focusing on delivery technologies. Products resulting from our research and development efforts, if approved for sale, may not compete successfully with our competitors' existing products or products under development.

8

We will depend on third parties to manufacture and market our products.

We do not have, and do not intend to develop, internal facilities for the manufacture of any of our products for clinical or commercial production. We will need to develop relationships with third-party manufacturing resources, enter into collaborative arrangements with licensees or other parties which have established manufacturing capabilities or elect to have other third parties manufacture our products on a contract basis. We expect to be dependent on such collaborators or third parties to supply us in a timely way with products manufactured in compliance with standards imposed by the FDA and foreign regulators. The manufacturing facilities of contract manufacturers may not comply with applicable manufacturing regulations of the FDA nor meet our requirements for quality, quantity or timeliness.

In addition, we have no direct experience in marketing, sales or distribution, and we do not intend to develop a sales and marketing infrastructure to commercialize pharmaceutical products. If we develop products eligible for commercial sale, we will need to rely on third parties such as licensees, collaborators, joint venture partners or independent distributors to market and sell those products. We may not be able to obtain access to a marketing and sales force with sufficient technical expertise and distribution capability. Also, we will not be able to control the resources and effort that a third party will devote to marketing our products. If we are unable to develop and maintain relationships for the necessary marketing and sales capabilities, we may fail to gain market acceptance for our products, and our revenues could be impaired.

We depend on key personnel to develop our products and pursue collaborations.

We are highly dependent on Dr. David Platt, President and Chief Executive Officer, and Dr. Anatole Klyosov. Dr. Klyosov is a member of our Scientific Advisory Board and he owns 50% of MIR International, Inc., which provides consulting services regarding our research and development. The loss of either of these persons, or failure to attract or retain other key personnel, could prevent us from pursuing collaborations or developing our products and core technologies. We have not entered into an employment agreement with Dr. Platt.

Recruiting and retaining qualified scientific personnel to perform research and development work are critical to our success. There is intense competition for qualified scientists and managerial personnel from numerous pharmaceutical and biotechnology companies, as well as from academic and government organizations, research institutions and other entities. In addition, we may face particular difficulties because there is a limited number of scientists

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

specializing in carbohydrate chemistry, a principal focus of our company. We expect to rely on consultants and advisors, including our scientific and clinical advisors, to assist us in formulating our research and development strategy. Any of those consultants or advisors could be employed by other employers, or be self-employed, and might have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to us. Such other employment, consulting or advisory relationships could place our trade secrets at risk, even if we require non-disclosure agreements.

A former employer of our President alleged in early 2001 a violation of a non-competition covenant expiring on June 29, 2002.

SafeScience, Inc. (now known as GlycoGenesys, Inc.), former employer of Dr. David Platt, our President and Chief Executive Officer, alleged in a letter dated February 15, 2001 that he violated his employment severance agreement dated June 1, 2000, and included an allegation that his engagement with our company violates his non-competition covenant with SafeScience. Dr. Platt responded in a letter dated February 19, 2001 that our business is not competitive because, among other things, we are developing methods to reduce toxicity of currently existing chemotherapy drugs, whereas SafeScience is engaged in new drug development. SafeScience indicated a

9

willingness to resolve these matters but attempts to set up a meeting were unsuccessful. SafeScience has not pursued the matter with Dr. Platt or our company. Dr. Platt's non-competition covenant with SafeScience expires on June 29, 2002. An evaluation cannot be made at this time of the likelihood of a favorable or unfavorable outcome, nor can any estimate be made as to the amount or range, if any, of potential loss. If SafeScience makes demands against us with respect to the allegations, we intend to vigorously contest all such allegations.

We face potential difficulties in obtaining product liability and related insurance.

We do not have product liability or other professional liability insurance. In the future, we may, in the ordinary course of business, be subject to substantial claims by, and liability to, persons alleging injury as a result of taking products we have under development. If we are successful in having products approved by the FDA, the sale of such products would expose us to additional potential product liability and other claims resulting from their use. This liability may result from claims made directly by consumers or by pharmaceutical companies or others selling such products. We do not currently have any product liability or professional liability insurance, and it is possible that we will not be able to obtain or maintain such insurance on acceptable terms or that any insurance obtained will provide adequate coverage against potential liabilities. Our inability to obtain sufficient insurance coverage at an acceptable cost or otherwise to protect against potential product liability claims could prevent or limit the commercialization of any products we develop. A successful product liability claim in excess of our insurance coverage could exceed our net worth. While we desire to reduce our risk by obtaining indemnity undertakings with respect to such claims from licensees and distributors of our products, we may not be able to obtain such undertakings and, even if we do, they may not be sufficient to limit our exposure to claims.

Health care cost containment initiatives may limit our returns.

Our ability to commercialize our products successfully will be affected by the ongoing efforts of governmental and third-party payors to contain or reduce

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

the cost of health care. Governmental and other third-party payors increasingly are attempting to contain health care costs by:

- o challenging the prices charged for health care products and services
- o limiting both coverage and the amount of reimbursement for new therapeutic products
- o denying or limiting coverage for products that are approved by the FDA but are considered experimental or investigational by third-party payors
- o refusing in some cases to provide coverage when an approved product is used for disease indications in a way that has not received FDA marketing approval

In addition, the trend toward managed health care in the United States, the growth of organizations such as health maintenance organizations, and legislative proposals to reform healthcare and government insurance programs could significantly influence the purchase of healthcare services and products, resulting in lower prices and reducing demand for our products.

Even if we succeed in bringing any products to the market, they may not be considered cost-effective and third-party reimbursement might not be available or sufficient. If adequate third-party coverage is not available, we may not be able to maintain price levels sufficient to realize an appropriate return on our investment in research and product development. In addition, legislation and regulations affecting the pricing of pharmaceuticals may change in ways adverse to us before or

10

after any of our proposed products are approved for marketing. While we cannot predict whether any such legislative or regulatory proposals will be adopted, the adoption of such proposals could make it difficult or impossible to sell our products.

Environmental regulations may affect our manufacturers and other contractors.

Pharmaceutical research and development involves the controlled use of hazardous materials including but not limited to certain hazardous chemicals and radioactive materials. In connection with research, development and manufacturing activities, biotechnology and biopharmaceutical companies are subject to federal, state and local laws, rules, regulations and policies governing the use, generation, manufacture, storage, air emission, effluent discharge, handling and disposal of certain materials, biological specimens and wastes. Since we do not anticipate building in-house research, development or manufacturing facilities, but plan to have these activities conducted by contractors and other third parties, we do not anticipate that we will be directly affected by environmental regulations. However, our contractors and others conducting research, development or manufacturing activities for us may be required to incur significant costs to comply with environmental and health and safety regulations in the future, and this could in turn affect our costs of doing business and might ultimately interfere with timely completion of research or manufacturing programs if those third parties are unable to comply with environmental regulatory requirements.

Our ability to conduct animal testing could be limited in the future.

Our research and development activities have involved, and will continue to

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

involve, animal testing. Such activities have been the subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop animal testing activities by pressing for legislation and regulation in these areas. To the extent the activities of these groups are successful, our business could be materially harmed.

Stock prices for biopharmaceutical and biotechnology companies are volatile.

The market price for securities of biopharmaceutical and biotechnology companies historically has been highly volatile, and the market from time to time has experienced significant price and volume fluctuations that are unrelated to the operating performance of such companies. Fluctuations in the trading price or liquidity of our common stock may adversely affect our ability to raise capital through future equity financings.

Factors that may have a significant impact on the market price and marketability of our common stock include:

- o announcements of technological innovations or new commercial therapeutic products by us, our collaborative partners or our present or potential competitors
- o announcements by us or others of results of preclinical testing and clinical trials
- o developments or disputes concerning patent or other proprietary rights
- o adverse legislation, including changes in governmental regulation and the status of our regulatory approvals or applications
- o changes in health care policies and practices
- o economic and other external factors, including general market conditions

11

In the past, following periods of volatility in the market price of a company's securities, securities class action litigation has often been instituted. If a securities class action suit is filed against us, we would incur substantial legal fees and our management's attention and resources would be diverted from operating our business in order to respond to the litigation.

Our stock is not listed on any exchange or quoted on Nasdaq.

We have not listed our capital stock on any exchange and do not foresee that in the near-term we would be able to meet the listing standards for any exchange or for the Nasdaq National Market or the Nasdaq SmallCap Market. We are taking steps to permit our shares to be traded over the counter including on the over-the-counter bulletin board (OTCBB) sponsored by the National Association of Securities Dealers. There may be, but we cannot assure, a market for our shares on the OTCBB. Accordingly, our stockholders may not find a market for their shares and be unable to sell their shares when they want or at a favorable price.

If our stock is a "penny stock," your ability to trade our shares could be adversely affected.

The SEC has adopted regulations imposing limitations upon the manner in which certain low priced equity securities, referred to as "penny stocks," are

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

publicly traded. Under these regulations, a penny stock is defined as any equity security that has a market price of less than \$5.00 per share, subject to certain exceptions. These exceptions include any equity security listed on a national exchange, the Nasdaq National Market System or SmallCap Market and any equity security issued by a company meeting specified requirements for net tangible assets or revenues. Unless an exception is available, the regulations require the delivery, prior to any transaction involving a penny stock, of a disclosure schedule explaining the penny stock market and the associated risks. The regulations also require certain broker-dealers who recommend penny stocks to persons other than established customers and certain accredited investors to make a special written suitability determination for the purchaser and receive the purchaser's written agreement to a transaction prior to sale. These requirements make it more difficult to effect transactions in penny stocks as compared to other securities.

Our common stock is not yet publicly traded. Since we do not meet any of the requirements that would exempt us from the \$5.00 per share market price requirement, our stock must trade above that level in order for it not to be classified as a "penny stock." We are uncertain that trading prices at this level can be established or sustained. Should trading prices fall below \$5.00 per share, our shares could be considered a "penny stock" and your ability to trade our shares could accordingly be adversely affected.

Purchasers of stock may be subject to substantial dilution.

We are offering our common stock to the public at a price that is substantially higher than the net tangible book value per share of our common stock, as discussed in "Dilution," below. If you purchase common stock that Pro-Pharmaceuticals is offering with this prospectus, you will therefore incur immediate and substantial dilution.

Four principal stockholders own enough shares to control the company.

Four of our principal stockholders, David Platt, James Czirr, Offer Binder and Anatole Klyosov, own or control approximately 80% of our outstanding shares of our common stock, and Dr. Platt and Mr. Czirr together own approximately 64%. Even if we sell all of the 1,428,572

12

shares that we are currently offering in this prospectus, the four stockholders named above would still control approximately 73% of our common stock, with Dr. Platt and Mr. Czirr together controlling about 58%. Some or all of these stockholders, acting in concert, will be able to continue to elect the Board of Directors and take other corporate actions requiring stockholder approval, such as recapitalization or other fundamental corporate action, as well as dictate the direction and policies of our company. Such concentration of ownership also could have the effect of delaying, deterring or preventing a change in control of the company that might otherwise be beneficial to stockholders.

13

FORWARD-LOOKING STATEMENTS

This prospectus contains "forward-looking" statements that involve risks and uncertainties. Forward-looking statements include statements about the desired or believed utility and market for our potential products, future of the biotechnology and biopharmaceutical industry, statements about future business

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

plans and strategies, and most other statements that are not historical in nature. Because forward-looking statements involve risks and uncertainties, there are factors, including those discussed below, that could cause actual results to be materially different from any future results, performance or achievements expressed or implied. Accordingly, readers should not place undue reliance on forward-looking statements. We undertake no obligation to publicly release the result of any revision of these forward-looking statements to reflect events or circumstances after the date they are made or to reflect the occurrence of unanticipated events.

USE OF PROCEEDS

If we sell all of the 1,428,572 shares we are offering by this prospectus through Atlas Capital, our estimated proceeds would be \$4,455,000 after deducting the estimated placement fee and offering expenses. We cannot assure you that we will succeed in selling any or all of the shares of common stock we are currently offering. See "Risk Factors -- We may not be able to sell all of the shares we are currently offering" for further discussion about risks connected with this offering.

We will not receive any proceeds from the sale of common stock by the selling security holders.

We expect to use approximately \$3,500,000 of the aggregate net proceeds of this offering to fund our research and development efforts, including ongoing development of our technologies, pre-clinical and clinical testing and other costs associated with our pharmaceutical discovery and development programs. The remainder of the aggregate net proceeds will be used for working capital and general corporate purposes including general and administrative (\$800,000), equipment and leaseholds (\$80,000) and contingency allowance (\$75,000).

The amounts actually expended for each purpose may vary significantly depending upon a number of factors, including:

- o the progress of our drug delivery research and development efforts
- o our ability to establish collaborative arrangements
- o progress with pre-clinical studies and clinical trials
- o the time and costs involved in obtaining regulatory approvals
- o the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims
- o competing technological and market developments
- o changes in our collaborative relationships, if any

14

- o costs associated with the acquisition of technology, if any
- o evaluation of the commercial viability of potential products

Based on current projections, we estimate that our existing capital resources, together with the net proceeds from this offering, will be sufficient to fund our requirements for approximately twelve months. Pending such uses, we intend to invest the aggregate net proceeds from this offering in short-term, investment-grade, interest-bearing securities. We may also use a portion of the

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

net proceeds to acquire or invest in businesses, products and technologies that are complementary to ours, although no agreements have been entered into as of the date of this prospectus with respect to any such acquisition or investment. See "Plan of Operation," below, for further discussion of our operating plans.

MARKET FOR OUR COMMON STOCK AND RELATED STOCKHOLDER MATTERS

Market for Our Common Stock

There is currently no market for our common stock. We anticipate that we will retain a market maker to apply for trading of our common stock on the Over-the-Counter Bulletin Board following effectiveness of this registration statement. Our articles of organization provide that our common stock may not be sold without our approval until the 90th day after the date our common stock is registered under the Securities Exchange Act of 1934. We registered our common stock under the Exchange Act by filing a Registration Statement on Form 10-SB, which became effective as of August 13, 2001. Accordingly, our common stock became eligible for transfer, subject to applicable federal and state securities law requirements, as of November 11, 2001.

Shares Subject to Future Issuance

Convertible Notes

As of December 31, 2001, we had outstanding \$195,000 principal amount of notes. The number of shares the holder has a right to receive upon early conversion is computed by dividing the unpaid balance of the principal and accrued and unpaid interest by 75% of the offering price of our most recent equity offering. This conversion price, however, may not exceed \$2.00. At maturity, the notes are automatically converted based on dividing the principal and accrued interest by \$0.50, assuming a minimum of 10,000,000 shares outstanding. The \$195,000 principal amount represents the notes that are outstanding following an early conversion offer we made to noteholders as described below under "Plan of Operation -- Liquidity and Capital Resources."

In April 2002, we extended the maturity date for the \$195,000 of outstanding notes for one year. In consideration for the extension, 48,750 shares of common stock will be issued to the holders of the outstanding notes.

Common Stock Warrants

Private Placement (terminated)

We began in May 2001 a private placement of securities consisting of 1,470,000 units, offered at \$3.50 each, of one share of our common stock and one warrant to purchase one share of our common stock. Such purchases resulted in our issuing 689,300 shares of our common stock and warrants to purchase 689,300 shares of our common stock. We granted one purchaser of a

15

large block of units an option to purchase an additional 200,000 units on the same terms as that investor's current purchase. For detail about this private placement, see "Plan of Operation -- Liquidity and Capital Resources" below. We abandoned the private placement as of December 3, 2001, and terminated all offering activity on or before that date.

Warrants Issued to Former Holders of Convertible Notes

In response to our offer for early conversion of our convertible notes,

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

holders of an aggregate of \$1,125,602 of principal amount of the convertible notes have requested conversion of their notes. This resulted in issuance of an additional 598,229 common stock purchase warrants identical to the warrants being offered in our terminated private placement.

Stock Incentive Plan

On October 18, 2001, our Board of Directors adopted the "Pro-Pharmaceuticals, Inc. 2001 Stock Incentive Plan" which permits awards of incentive and non-qualified stock options and other forms of incentive compensation to employees and nonemployees such as directors and consultants. The Board reserved 2,000,000 of our shares of common stock for awards pursuant to the plan, all of which reserved shares could be awarded as incentive stock options. The Board agreed to recommend the plan to our stockholders for approval at the next annual or special meeting of stockholders. As of April 8, 2002, we have granted Burton Firtel, a director of our company, a non-qualified stock option under the plan to purchase 200,000 shares of common stock. The option is immediately exercisable as to 120,000 shares. See "Management -- Compensation of Directors and Advisors" for further information about this option grant.

Shares Eligible for Sale Pursuant to Rule 144 under the Securities Act

As of April 8, 2002, 15,524,410 shares of our common stock are outstanding, including 1,221,890 shares which were issued as a dividend to the stockholders of Developed Technology Resource, Inc., and 12,354,670 shares which were issued to the former shareholders of Pro-Pharmaceuticals (Massachusetts). All of our outstanding shares, except for the 1,221,890 shares issued as a dividend to the Developed Technology stockholders, are restricted securities within the meaning of Rule 144 under the Securities Act of 1933 and may not be sold in the absence of registration under the Securities Act unless an exemption from registration is available, including an exemption contained in Rule 144 under the Securities Act.

In general, under Rule 144 as currently in effect, a person (or persons whose shares are aggregated), including an affiliate, as that term is defined in Rule 144 under the Securities Act, who has beneficially owned shares for at least one year is entitled to sell, within any three-month period, a number of such shares that does not exceed the greater of (1) one percent of the then outstanding shares of common stock (approximately 155,244 shares as of April 8, 2002) or (2) the average weekly trading volume in the common stock in the Over-the-Counter market during the four calendar weeks preceding the date on which notice of such sale is filed, provided certain requirements concerning availability of public information, manner of sale and notice of sale are satisfied. In addition, our affiliates must comply with the restrictions and requirements of Rule 144, other than the one-year holding period requirement, in order to sell shares of common stock which are not restricted securities.

Under Rule 144(k), a person who is not an affiliate and has not been an affiliate for at least three months prior to the sale and who has beneficially owned shares for at least two years may resell such shares without compliance with the foregoing requirements. In meeting the one- and two-year holding periods described above, a holder of shares can include the holding periods of a prior owner who was not an affiliate. The one- and two-year holding periods described above do

not begin to run until the full purchase price or other consideration is paid by the person acquiring the shares from the issuer or an affiliate.

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

The 12,354,670 shares of our common stock issued to the shareholders of Pro-Pharmaceuticals (Massachusetts) in exchange for their Pro-Pharmaceuticals (Massachusetts) common stock will become eligible for sale pursuant to Rule 144 under the Securities Act on May 15, 2002, which is one year from the date of the exchange. We have no agreements with any holder of our common stock or warrants that would require us to register any common stock under the Securities Act for sale by security holders.

Holders

As of April 8, 2002, there were 212 holders of record of our common stock, although we believe that there are additional beneficial owners of our common stock who own their shares in "street name."

Dividends

There have been no cash dividends declared on our common stock since our company was formed. Dividends are declared at the sole discretion of our Board of Directors.

PLAN OF OPERATION

This Plan of Operation and other parts of this prospectus contain forward-looking statements that involve risks and uncertainties. All forward-looking statements included in this document are based on information available to us on the date hereof, and we assume no obligation to update any such forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including those set forth in "Risk Factors" and elsewhere in this prospectus.

We were incorporated in January 2001 for the purpose of effecting a business combination with Pro-Pharmaceuticals, Inc., a Massachusetts corporation. The transaction included a merger in which we are the surviving corporation. The business combination has been accounted for using purchase accounting, with the assets and liabilities of the acquired company being recorded at fair value. The merger and related transactions are discussed below under "Business -- Initial Corporate Organization, Acquisition and Merger."

Our capital resources to date consist of (i) the proceeds of a private placement of convertible notes issued and sold by the predecessor Massachusetts company in anticipation of its being acquired by us, (ii) the proceeds of a private placement begun in May 2001 of our common stock and stock purchase warrants and (iii) the proceeds of our public offering of common stock begun in December 2001 pursuant to this registration statement on Form SB-2 as originally filed and declared effective by the SEC. Each is further described below.

Commencing in December 2000 and continuing through May 2001, Pro-Pharmaceuticals (Massachusetts) issued convertible notes with an aggregate principal amount of \$1,320,602 to "accredited investors" as such term is defined in Regulation D promulgated under the Securities Act of 1933. These notes are now our corporate obligations as a result of the merger with Pro-Pharmaceuticals (Massachusetts). The notes have an interest rate of 10% per year and mature one year from their issuance dates. The number of shares the holder has a right to receive upon early conversion is computed by dividing the unpaid balance of the principal and accrued and unpaid interest by 75% of the offering price of our most recent equity offering. This conversion price,

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

however, may not exceed \$2.00. At maturity, the notes are automatically converted based on dividing the principal and accrued interest by \$0.50, assuming a minimum of 10,000,000 shares outstanding. Pursuant to our early conversion offer, described below, holders of an aggregate of \$1,125,602 of principal and accrued interest of the convertible notes have requested conversion of their notes.

We began as of May 25, 2001 a private placement of securities exempt from registration pursuant to Rule 506 of Regulation D under the Securities Act of 1933 in order to raise \$5,145,000 to cover our expenditures. We abandoned this private placement as of December 3, 2001, and terminated all offering activity on or before that date. Purchasers under the private placement had to qualify as "accredited investors" as such term is defined in Regulation D. The offered securities comprised up to 1,470,000 units, offered at \$3.50 each, of one share of our common stock and one 4-year warrant exercisable at \$6.50 to purchase one share of our common stock. We sold 689,300 units as of the date we abandoned the offering. The warrant is subject, following written notice, to acceleration if either (i) we file a New Drug Application with the FDA, or (ii) our stock is listed on an exchange and its closing price exceeds \$11.00 on any 10 trading days within a period of 20 consecutive trading days or, if our stock is quoted on the NASDAQ National Market System or Small Cap Market, or over-the-counter, and the average of the closing bid and asked prices thereon exceeds \$11.00 on any 10 trading days within a period of 20 consecutive trading days.

In connection with agreements with three investors in this offering who were each willing to invest a substantial amount of funds, we sold units at \$3.00 each, as follows: 133,400 of the units for a total of \$400,200; 66,700 units for a total of \$200,100; and 150,000 units for a total of \$450,000. We reduced each investor's warrant exercise price to \$5.00, and changed the warrant acceleration provision to lower the 10-day closing price threshold to \$10.00. We also granted the earliest of these investors an option to purchase an additional 200,000 units on the same terms as that investor's current purchase. The option is exercisable at any time until 30 days after we notify the investor of our receipt of notice that an investigational new drug application filed by us with the FDA has become effective for any one of our compounds.

As of the termination of this private placement in December 2001, we had received proceeds of \$2,237,500 from the sale of the securities offered in this private placement. Such purchases will result in our issuing 689,300 shares of our common stock and warrants to purchase 889,300 shares of our common stock.

We have requested that the holders of the convertible notes described above convert them, in accordance with their terms, to shares of our common stock prior to the notes' maturity dates. In order to encourage early conversion by September 7, 2001, we offered to issue each noteholder who converts a common stock purchase warrant identical to the warrant offered in our terminated private placement. In the case of a noteholder who accepted our offer, the warrant we issued is exercisable to purchase such number of shares as is equal to the number of shares of our common stock that the holder receives as of the conversion of the note. In response to our offer, holders of an aggregate of \$1,125,602 of principal amount of the convertible notes have requested conversion of their notes.

Regardless of whether a noteholder accepted our early conversion offer or later decides to convert each of our noteholders is entitled to receive, as "additional consideration" for originally purchasing the note, one-half (1/2) share of our common stock for each dollar of principal. We have completed our issuance an aggregate of 660,321 of such "additional compensation" shares. All shares of common stock issued upon conversion of the notes are "restricted securities" as defined in Rule 144 under the Securities Act.

In April 2002, we extended the maturity date for the \$195,000 of outstanding notes for one year. In consideration for the extension, 48,750 shares of common stock will be issued to the holders of the outstanding notes.

On December 13, 2001, we commenced a public offering of 1,428,572 shares of our common stock, at a price to the public of \$3.50 per share, pursuant to this registration statement on Form SB-2 as originally filed and declared effective by the SEC on December 12, 2001. We anticipated concluding the offering on February 11, 2002 but extended the offering until June 11, 2002. As of April 8, 2002, we had sold but not issued approximately 50,570 shares pursuant to our public offering.

As of December 31, 2001, we had approximately \$1,491,000, and as of April 8, 2002 approximately \$970,000, in cash and cash equivalents. We have budgeted expenditures for the twelve-month period ending December 31, 2002, of \$5,600,000, comprised of anticipated expenditures for research and development (\$4,400,000), general and administrative (\$1,000,000), equipment and leaseholds (\$100,000) and contingency allowance (\$100,000).

Our financial statements have been presented on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Pro-Pharmaceuticals is in the development stage, has incurred a net loss since inception of approximately \$4,155,000 and expects to incur additional losses in the near future. Successful completion of our development program and, ultimately, the attainment of profitable operations is dependent upon future events, including maintaining adequate financing to fulfill our development activities and achieving a level of sales adequate to support our cost structure. We are actively seeking additional financing to fund future operations and future significant investments in the business. However, there can be no assurance that we will be able to obtain financing on acceptable terms, or at all.

Additional funds may be raised through additional equity financings, as well as borrowings and other resources. With the capital we have raised to date, and the additional \$5,000,000 under the offering described in this prospectus that we are attempting to raise, we believe that we will be able to proceed with our current plan of operations and meet our obligations for approximately the next twelve months. If we do not raise the additional funds, we will have to cut our research and development expenditures, which would substantially slow progress that we might expect to make during the next twelve months in development of our business including commencement of clinical trials.

We expect to generate losses from operations for several years due to substantial additional research and development costs, including costs related to clinical trials. Our future capital requirements will depend on many factors, in particular our progress in and scope of our research and development activities, and the extent to which we are able to enter into collaborative efforts for research and development and, later, manufacturing and marketing products. We may need additional capital to the extent we acquire or invest in businesses, products and technologies. If we should require additional financing due to unanticipated developments, additional financing may not be available when needed or, if available, we may not be able to obtain this financing on terms favorable to us or to our stockholders. Insufficient funds may require us to delay, scale back or eliminate some or all of our research and development programs, or may adversely affect our ability to operate as a going concern. If additional funds are raised by issuing equity securities, substantial dilution to existing stockholders may result.

CAPITALIZATION

The following table sets forth our capitalization as of December 31, 2001, and also our capitalization as adjusted to reflect the sale of 1,428,572 shares of our common stock that we are offering with this prospectus, at an assumed maximum public offering price of \$3.50 per share, and receipt of net proceeds from this sale of \$4,455,000 reflecting gross proceeds less placement agent commissions of \$425,000 (assuming all shares in offering were sold through placement agent) and estimated offering costs of \$120,000. See "Use of Proceeds" for further information about our anticipated proceeds to us from this offering.

	December 31, 2001	
	Actual	As Adjusted
	-----	-----
Common voting shares, \$0.001 par value, 100,000,000 shares authorized and 15,524,410 shares outstanding actual and 16,952,982 shares outstanding pro forma as adjusted (1)	\$ 15,524	\$ 16,953
Undesignated shares, \$0.01 par value, 5,000,000 shares authorized, none issued	--	--
Additional paid-in capital	5,450,106	9,903,677
Deferred compensation	(91,575)	(91,575)
Deficit accumulated during development stage	(4,158,210)	(4,158,210)
	-----	-----
	\$ 1,215,845	\$ 5,670,845
	=====	=====

- (1) The number of shares outstanding at December 31, 2001, excludes approximately 50,570 shares of common stock sold, but not yet issued, after December 31, 2001 through March 31, 2002. Also excluded are 2,078,091 shares issuable pursuant to the exercise of stock options and warrants and conversion of convertible debt.

SELECTED FINANCIAL DATA

The income statement data for the period from July 10, 2000 (inception) through December 31, 2000, and balance sheet data at December 31, 2000, are derived from financial statements that have been audited by Scillia Dowling & Natarelli LLC, which are included elsewhere in this prospectus. The income statement data for the twelve months ended December 31, 2001, and balance sheet data at December 31, 2001, are derived from financial statements that have been audited by Deloitte & Touche, LLP, which are included elsewhere in this prospectus. You should read the data set forth below in conjunction with "Plan of Operation," above, and the financial statements and notes included in this prospectus.

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

	Period from Inception (July 10, 2000) to December 31, 2000 -----	Year Ended December 31, 2001 -----	Cumula sin Incep -----
Income Statement Data			
Revenue	\$ --	\$ --	\$
Net loss	\$ (184,582)	\$ (3,970,273)	\$ (4,15
Net loss per share			
Basic and diluted	\$ (0.01)	\$ (0.29)	
Weighted average outstanding shares			
Basic and diluted	12,354,670	13,601,795	

	December 31, 2000 -----	December 31, 2001 -----
Balance Sheet Data		
Total assets	\$ 227,940	\$ 1,766,547
Working capital	\$ 23,133	\$ 1,021,239
Stockholders' equity	\$ 46,328	\$ 1,215,845

BUSINESS

Initial Corporate Organization, Acquisition and Merger

We were incorporated as "DTR-Med Pharma Corp." under Nevada law in January 2001 for the purpose of acquiring all the outstanding stock of our predecessor, Pro-Pharmaceuticals, Inc., which was a Massachusetts corporation engaged in a business we desired to acquire. From our incorporation until just before the acquisition, we were a wholly-owned subsidiary of Developed Technology Resource, Inc., a Minnesota corporation whose common stock is publicly traded on the Over-the-Counter Bulletin Board. In exchange for 1,221,890 shares of our common stock, Developed Technology transferred to us contractual rights that are described below under "Business of Pro-Pharmaceuticals -- Cancer Detection Technology." As part of that process, Developed Technology distributed its holdings of our common stock to its shareholders of record as of May 7, 2001. In anticipation of the acquisition of the Massachusetts company, we changed our name to "Pro-Pharmaceuticals, Inc."

On May 15, 2001, we acquired all of the outstanding common stock of the Massachusetts corporation. We acquired these shares in exchange for 12,354,670 shares of our common stock. As a result, that corporation became our wholly owned subsidiary, and its shareholders through an exchange owned approximately 91% of the outstanding shares of our common stock, with the

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

Ownership of Certain Beneficial Owners and Management" for information about the ownership of our common stock. After the acquisition, we merged with the Massachusetts corporation and are the surviving corporation in the merger. The merger was treated as a capital transaction and was accounted for as a reverse merger in which Pro-Pharmaceuticals (Massachusetts) was the accounting acquirer.

Concurrent with the acquisition, all of our original officers and directors resigned and were succeeded by the officers and directors of the predecessor Massachusetts corporation, except for Peter Hauser, who has served a director from our incorporation in January 2001. He had also served as Vice President from that time until the acquisition.

As required by the stock exchange agreement that effected the acquisition, we filed a registration statement in June 2001 on Form 10-SB with the Securities and Exchange Commission in order to register our common stock under the Securities Exchange Act of 1934. The registration of our common stock under the Exchange Act became effective on August 13, 2001. Our articles of organization provide that our common stock may not be sold without our approval until the earlier of May 1, 2003 or the 90th day after the date our common stock is registered under the Securities Exchange Act of 1934. Accordingly, our common stock became eligible for transfer, subject to applicable federal and state securities law requirements, as of November 11, 2001. We anticipate that we will retain a market maker to apply for trading of our common stock on the Over-the-Counter Bulletin Board following effectiveness of this registration statement.

We are continuing the business of Pro-Pharmaceuticals (Massachusetts), which has been attempting to develop a technology that will reduce the toxicity and improve the efficacy of current drug therapies, including cancer chemotherapies, by combining the drugs with a number of specific carbohydrate compounds. This is now the principal focus of our business, and is the basis for the business discussion included in this registration statement.

Our address is 189 Wells Avenue, Suite 200, Newton, Massachusetts 02459. Our telephone number is (617) 559-0033, fax number is (617) 928-3450, e-mail address is foley@pro-pharmaceuticals.com, and our website address is www.pro-pharmaceuticals.com.

Business of Pro-Pharmaceuticals

Overview

We are an early-stage research and development pharmaceutical company that intends initially to identify, develop and seek regulatory approval of technology that will reduce toxicity and improve the efficacy of currently existing chemotherapy drugs by combining the drugs with a number of specific carbohydrate compounds. Our fundamental objective is to increase the body's tolerance to the drugs by enabling delivery of the drugs while protecting healthy tissue. This would also permit use of larger doses of the drugs, since current dosages are generally limited due to concerns relating to their toxic effects on healthy cells. Our carbohydrate-based drug delivery system may also have applications for drugs now used to treat other diseases and chronic health conditions.

In technical terms, we seek to "reformulate" existing cancer chemotherapy drugs with non-toxic carbohydrate-based compounds that recognize and adhere to specific binding sites on the surface of cancer cells. Reformulation of chemotherapy drugs already approved by the U.S. federal Food and Drug Administration has the following benefits for our business:

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

- o Our carbohydrate-based drug delivery system requires less time for development and FDA approval, and thus reaches the market sooner, because the active chemotherapy drugs are already approved and in widespread use for cancer treatment.
- o We expect fewer risks in drug development because our carbohydrate-based compounds would be combined with drugs already in widespread use. Use of carbohydrate compounds with increased capacity to bind to receptors only on cancer cells and combining the drug with a harmless carbohydrate polymer will reduce the toxic effect on healthy cells and permit better calibration (including possible increase) of dosages to diseased tissue.
- o We foresee a ready demand for chemotherapy that is less toxic and has greater efficacy. We believe the pharmaceutical industry would respond favorably to drug delivery systems to upgrade chemotherapies which patients would tolerate more easily. The industry would likely also be receptive to patent-protected drug delivery systems that "attach" to chemotherapies whose patent protection has expired.
- o We believe that the development of drug delivery systems to upgrade these widely used drugs can be accomplished with much less investment compared to the typical expenditures made by large pharmaceutical companies for a new drug launch.

Cancer and Therapy Issues

Cancer is a disease characterized by uncontrolled growth and spread of abnormal cells. The disease may be caused by patient-specific factors such as genetic predisposition, immune deficiency, hormones, diet and smoking, or external factors such as exposure to a toxic environment. It is the second leading cause of death in the United States, resulting in over 550,000 deaths annually. The National Cancer Advisory Board reports that more than 8 million persons in the U.S. have cancer. Estimates claim that approximately one in three Americans will be diagnosed with the disease their lifetime. About 1.2 million new cases are diagnosed in the U.S. each year. As populations age in the U.S., Canada and other industrialized nations, the incidence of the disease is expected to increase. About 6 million persons worldwide die annually from cancer.

The most widely used methods to treat cancer are surgery, radiation and chemotherapy. Cancer patients often receive a combination of these treatments, and about half of all patients receive chemotherapy. Both radiation and chemotherapy have significant limitations that often result in treatment failure. In the case of chemotherapy, these limitations include:

- o Toxicity. Most chemotherapy agents kill cancer cells by disrupting the cell division process. Cells are killed once they begin to undergo division and replication. Although these agents are effective on cancer cells, which generally grow rapidly through cell division, they also kill healthy non-cancerous cells as these cells undergo ordinary division. This is particularly apparent in fast-growing normal cells, such as blood cells forming bone marrow, in the digestive tract, hair follicles, and reproductive cells. As the chemotherapy harms healthy tissue, the effectiveness of the drug is limited because dosage levels and treatment frequency cannot exceed tolerance levels for noncancerous cells. Moreover, the chemotherapy regimen often dramatically diminishes the quality of a patient's life through its physical and emotional side effects.

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

- o Inability to Selectively Target Diseased Cells. The administration of chemotherapy occurs in such a way that the drug reaches both healthy and diseased tissue. Normal cells are generally as receptive as tumors to the toxic effects of chemotherapy. Without the ability to target the drug exclusively to cancerous tissue, chemotherapy dosages must

23

be kept within a range that healthy tissue can tolerate, thus reducing the optimal effectiveness of chemotherapy on diseased tissue.

Our Business Strategy and Initial Objectives

We seek to increase the effectiveness of current cancer treatment and other drugs. The initial objectives of our business strategy are as follows:

- o Verify and extend the carbohydrate-based drug enhancement concept encompassing our approach for developing novel cancer chemotherapy products.
- o Expand and enhance clinical applications of at least five widely used chemotherapy drugs (5-Fluorouracil, Adriamycin, Taxol, Cytosan and Cisplatin) by combining them with our carbohydrate-based drug delivery system.
- o Demonstrate the safety and efficacy of such product candidates by means of preclinical evaluation and submitting investigational new drug ("IND") applications to the FDA.
- o Accelerate commercialization by identifying products that qualify for fast-track designation by the FDA (further described below). We plan to develop products to be used in treatment of types and stages of cancer for which treatments are now inadequate. The FDA has adopted fast-track and priority procedures for accelerating the approval of oncology agents addressing such needs, potentially reducing the time required to bring new drugs to market. Once approved, we would seek to expand the market potential of our products by seeking approval for indications in larger cancer patient populations.
- o Leverage our carbohydrate-based drug enhancement technology by applying it to other FDA-approved drugs, including drugs for conditions or ailments other than cancer, that would benefit from reduced toxicity and/or greater efficacy. This strategy would enable us to increase the portfolio of drugs to which our technology may be applied without corresponding development risk and expense of creating new drugs.
- o Apply our drug enhancement system with the aim of extending the patent life of current drugs, or in some cases drugs with expired patents, creating new patent protection. For example, the patent protections of the five cancer drugs with which we propose to work have all expired or long been in the public domain. Non-cancer drugs whose patents have expired, and that we might apply our carbohydrate-based drug enhancement technology to include: Prozac (anti-depressant manufactured by Eli Lilly and Company); Prilosec (anti-ulcerative manufactured by AstraZenaca PLC); and Zoloft (anti-depressant manufactured by Pfizer Inc.).

Drug Delivery Technologies

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

General

The ultimate objective of enhanced drug delivery is to control and optimize the localized release of a drug at the target site and rapidly eliminate from the body the portion of the drug that was not delivered to the diseased tissue. Conventional drug delivery systems such as controlled release, sustained release, transdermal systems, and others are based on a physical erosion process for delivering active product into the systemic circulation over time with the objective of improving compliance by patients with a therapy regimen. These systems do not address the biologically important issues such as site targeting, localized release and elimination of undelivered drug from the body. The major factors that impact the achievement of this ultimate goal are:

24

- o Physical characteristics of a drug. These characteristics affect, among other things, the drug's interactions with the intended pharmacological target sites and undesired areas of toxicity; and
- o Biological characteristics of the diseased area. These characteristics impact the ability of a drug to selectively interact with the intended target site to allow the drug to express the desired pharmacological activity.

Both of these factors are important in increasing efficacy and reducing toxicity of cancer drugs. Biotechnology affords a new opportunity in drug delivery techniques by taking advantage of biological mechanisms such as drug-cell recognition and interactions, and particular physical characteristics of cancerous tissue.

Our Focus: Carbohydrate-Based Drug Enhancement Technology

We are attempting to develop a carbohydrate-based drug delivery technology to direct cancer drugs more selectively to tumor tissue so as to reduce the toxic side effects and improve the tumor reduction capacity of chemotherapy drugs now in use. Carbohydrates are found in the structural elements of cell walls and, among other functions, serve as recognition elements in biomolecules, enabling molecule-cell recognition, and hence, molecular targeting. The dense concentration of chemical functional groups within carbohydrates compared to other chemicals suits them for use in cell recognition applications in biological systems.

Our drug enhancement technology is intended to take advantage of the following biological mechanisms to improve drug delivery:

- o Disease-specific carbohydrate recognition; and
- o Enhanced permeability and retention in tumors.

Our technology does not change the chemistry of the drugs themselves, but rather "attaches" cancer drugs to proprietary carbohydrate compounds, which interact with sugar-specific proteins on the surface of the tumor cell. Because of these cell surface interactions, we believe that these compounds will increase cell permeability, resulting in increased targeted absorption of drugs by cancer cells. These cell surface interactions may also reduce the cells' ability to adhere to each other as well as to normal tissue, resulting in diminished ability of cancer cells to metastasize, or spread to other tissue systems.

Our preliminary studies have led to the identification of certain mannans,

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

a group of polysaccharides, as a potential drug delivery system. Polysaccharides are molecules consisting of one or more types of sugars. In the case of mannans, the principal component is the sugar mannose, which is similar in many respects to glucose. While mannans can be isolated from plant or microbial sources, we use mannans isolated from plants. We believe that a mannan with suitable chemical structure and composition, when attached to or combined with the active agent of a chemotherapy drug, increases cellular membrane fluidity and permeability, thereby assisting delivery of the drug. Also, our studies have shown that mannans of a certain structure may be able to protect healthy tissue from the toxic effects of chemotherapy drugs, and also may be able to increase therapeutic efficacy of such drugs.

25

Initial Chemotherapy Applications

We believe that our carbohydrate-based drug enhancement technology applies to essentially any oncology drug whose delivery to the target can be improved by utilizing sugar-specific recognition at the cancer cell surface. Initially, we are studying the effect of our carbohydrate-based system on the toxicity and efficacy of selected cancer drugs. We have conducted preliminary studies that indicate that certain of our mannans, when combined with some of these drugs, may significantly reduce the toxic effects of the drugs and may also increase therapeutic efficacy of such drugs.

Our initial program is designed to be "risk-contained" in that it will focus on proven drugs for which there are already a great deal of data on their therapeutic efficacy and toxicity, along with an accumulated knowledge of their limitations. We intend to apply our drug delivery technology initially to five widely used chemotherapy agents: 5-Fluorouracil, Adriamycin, Taxol, Cytosan and Cisplatin. Each of these drugs is among the most popular drugs used in cancer chemotherapy treatment in the United States, and for each of these drugs there is a strong need for improving their therapeutic efficacy and decreasing their toxicity.

- o 5-Fluorouracil (5-FU) is a fluorinated pyrimidine (a nucleic acid component). It interferes with the synthesis of DNA and inhibits the formation of RNA. Since DNA and RNA are essential for cell division and growth, the effect of 5-FU provokes unbalanced growth and death of the cell. The effect of DNA and RNA deprivation is most marked on those cells which grow more rapidly and which take up the 5-FU at a more rapid rate, such as cancer cells. 5-FU is effective against cancers of the colon, rectum, breast, stomach and pancreas. This drug is also toxic, resulting in side effects such as nausea, vomiting, mouth sores, gastrointestinal ulceration and bleeding, loss of hair, skin darkening and fatigue. 5-FU is manufactured by Roche Laboratories for intravenous administration. Originally patented in the late 1950s, its patent protection has expired.
- o Adriamycin (generic name -- doxorubicin hydrochloride) is a cytotoxic agent that selectively kills malignant cells and causes tumor regression. It binds to the DNA, and presumably inhibits nucleic acid synthesis. It is used to treat, among others, leukemia, cancers of the breast, ovaries, bladder, stomach and thyroid, as well as Hodgkin's and non-Hodgkin's lymphoma. Adriamycin is toxic, resulting in side effects such as nausea, vomiting, loss of hair, mouth sores, colon ulceration and heart o damage. It is manufactured by Pharmacia Upjohn for intravenous administration. Originally patented in 1971, its patent protection has expired.

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

- o Taxol (generic name -- paclitaxel) is a relatively new anti-leukemic and anti-tumor agent, possessing a cytotoxic activity. It suppresses cell division by binding to so-called microtubules that form in a cell's nucleus to help move the chromosomes around during the division process. Taxol is most effective against ovarian and advanced breast cancers, particularly after failure of standard chemotherapy. Studies indicate that it might be effective against leukemia, lung carcinoma, colon carcinoma, renal carcinoma, melanoma, and CNS carcinoma. Taxol is toxic, and patients receiving it often develop problems ranging from rashes, drop in blood pressure and anemia to major breathing problems, hives and/or fluid buildup around the heart and bone marrow suppression. Almost all patients experience hair loss from Taxol, and some patients experience severe hypersensitivity reactions to Taxol. It is manufactured by Bristol-Myers-Squibb Company for intravenous administration. We believe that there are no patents covering the composition of Taxol (paclitaxel).

26

- o Cytoxan (generic name -- cyclophosphamide) has action leading to cross-linking of RNA of tumor cells, and thereby interferes with the growth of susceptible rapidly proliferating malignant cells. It is effective against a range of cancers, such as malignant lymphomas, Hodgkin's disease, various leukemias, and cancer of the breast and ovaries. This drug is toxic, with side effects including nausea, vomiting, anorexia, diarrhea, skin rash and darkening and, in extreme cases, heart damage or failure, and secondary malignancies. It is manufactured by Bristol-Myers-Squibb Company for intravenous and oral administration. We believe that there are no patents covering the composition of Cytoxan (cyclophosphamide).
- o Cisplatin appears to act by inhibiting DNA synthesis. It is effective against metastatic testicular and ovarian tumors (typically in combination with other chemotherapeutic agents, such as Cytoxan, above), and advanced bladder cancer. This drug is toxic, with side effects including renal toxicity, nausea, vomiting, anorexia, diarrhea and anemia. It is manufactured as PLATINOL(R) by Bristol-Myers-Squibb Company for intravenous injection. We believe that there are no patents covering the composition of Cisplatin.

Preclinical Animal Studies; Investigational New Drug Application

As discussed below, using independent laboratories we have conducted preclinical animal experiments to study the toxicity and efficacy of 5-Fluorouracil (5-FU), and are also conducting preclinical animal experiments to study the toxicity and efficacy of Adriamycin in combination with our mannan compounds. The preclinical data we obtained from the studies with 5-FU will be included in an Investigational New Drug, or IND, submission that we plan to make to the FDA in the first half of 2002. We have already submitted some study results to the FDA on a preliminary basis.

Toxicity Studies

Results of one toxicity study conducted in early 2001 indicate that one of our mannan compounds, named Davanat-1, may significantly decrease the toxicity of 5-FU. Ten groups of five animals each were used. In five groups, treated respectively with a placebo and one of four different mannans provided by us, the animals showed no signs of toxicity. That was expected because the animals were not receiving the toxic drug, and the mannans were not expected to be toxic at all. In four groups, treated respectively with 5-FU alone and 5-FU in

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

combination with either of three of the mannans, the animals showed signs of severe toxicity. In one group, treated with 5-FU in combination with the fourth mannan, Davanat-1, no clinical signs of toxicity were observed. This provides a preliminary indication of potential reduction in cancer drug toxicity by a carbohydrate-based addition to the cancer drug.

A second, similar study, also conducted in early 2001, was performed to test a potential reduction of toxicity of another anticancer drug, Adriamycin, in combination with each of two mannan compounds selected for the study. Results indicate that one of the mannan compounds may decrease the toxicity of Adriamycin. In two groups, treated with Adriamycin alone and Adriamycin in combination with one mannan, the animals showed signs of severe toxicity. In one group, treated with the same amount of Adriamycin in combination with the second mannan, four out of the five animals in the group did not show any clinical signs of toxicity. Again, this provides a preliminary indication of potential reduction in cancer drug toxicity by a carbohydrate-based addition to the cancer drug. The fact that two different cancer drugs with chemically unrelated structures showed a marked reduction of their toxicity in combination with particular mannans indicates that there might be some fundamental underlying biological reasons, related to the mannans rather than to the drugs, for the reduction in toxicity.

27

The above toxicity studies were conducted by Toxikon Corporation, a comprehensive compliance FDA-registered service testing laboratory in Bedford, Massachusetts, that is not affiliated with Pro-Pharmaceuticals. Please see "Research" below, for further information about Toxikon Corporation.

In four subsequent preclinical experiments conducted in June and September 2001, we studied on larger animals the toxicity reduction of 5-FU in combination with Davanat-1, which had demonstrated toxicity reduction in the prior 5-FU study. These experiments were performed in accordance with FDA guidelines and recommendations on rats (acute and long-term toxicity study) and dogs (acute and long-term toxicity study) measuring the effect of the 5-FU/Davanat-1 combination on blood structure and survival of these animals. Preliminary results indicate that the 5-FU/Davanat-1 combination decreased toxicity using this measure because it resulted in lower animal mortality and decreased loss of blood structure components in comparison to the results of tests which administered 5-FU alone.

These four experiments were conducted by Redfield Laboratories, Inc., based in Redfield, Arkansas and licensed by the U.S. Department of Agriculture to conduct research in laboratory animals. Testing conditions at Redfield Laboratories are in compliance with the federal Animal Welfare Act. Redfield Laboratories is not affiliated with Pro-Pharmaceuticals.

Efficacy Study

A preliminary study was performed to test a potential change in therapeutic efficacy of 5-FU in a combination with Davanat-1, which had decreased toxicity of the drug in healthy animals (see the first study described in " -- Toxicity Studies," above). The study was motivated by the desire to test the possibility that Davanat-1 might diminish both toxicity and efficacy in parallel, if the Davanat-1 were merely competing with 5-FU for binding with cells, healthy or cancerous. Results of the study demonstrated, however, that Davanat-1, which may decrease toxicity of 5-FU, may also increase efficacy of the drug when the drug combined with Davanat-1 is administered into cancer-carrying animals. In this study, we ascertained a decrease in tumor size following administration of 5-FU alone as well as administration of the 5-FU/Davanat-1 combination. When the

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

5-FU/Davanat-1 combination was administered, the time for the tumor to quadruple in size in the animals increased from 24 days (5-FU alone administered) to 56 days (5-FU/Davanat-1 combination administered) relative to 12 days for control animals (no drug administered).

The above efficacy study was conducted by Southern Research Institute in Birmingham, Alabama. Southern Research Institute is an independent, not-for-profit contract research organization that is not affiliated with our company. Please see "Research" below, for further information about Southern Research Institute.

Carbohydrate-Cancer Drug Formulations

We are currently developing formulations of carbohydrates linked to anti-cancer drugs. We have chemically synthesized four novel products that are carbohydrate derivatives of Adriamycin, and have conducted preclinical animal experiments, studying both toxicity (on healthy animals) and efficacy (on cancer-carrying animals). Preliminary results of these experiments indicate that all four of the synthesized carbohydrate-Adriamycin compounds, and particularly one, named Galactomycin, are significantly less toxic compared with the original Adriamycin, and demonstrate therapeutic efficacy as well. In the case of Galactomycin, the preliminary results indicated a therapeutic efficacy higher than that for the parent Adriamycin. These studies were conducted at the Academy of Medical Sciences, Moscow, Russia.

28

Although the foregoing studies are encouraging, the results achieved in preclinical studies with animals are often not duplicated in human patients. Please see "Risk Factors That May Affect Results -- Our product candidates will be based on novel technologies" below.

IND Application; Anticipated Phase I Study

We have engaged Averion, Inc., of Framingham, Massachusetts, for the purpose of assisting us in matters including statistical analysis, pre-IND support services and design and implementation of our future Phase I study. To date, Averion has prepared a statistical analysis report and has conducted pre-IND support services, all in accordance with work assignments as they and we establish from time to time. Work assignments dated February 20, 2002 and February 26, 2002, in connection with statistical analysis support, provide that those services are to be charged on an hourly basis. As of April 8, 2002, charges have aggregated approximately \$89,000 for those services. A work assignment dated March 1, 2002 concerns services in connection with our anticipated Phase I study, not yet started, with a budget cost estimate of \$570,000.

Cancer Detection Technology

We have an indirect royalty interest in a cancer detection technology that may be applied to the detection of soft tissue nodules in human organs, and may thus assist in the detection of cancerous tissue. A diagnostic system has been developed which is based on this detection technology. This system uses pressure to measure the elasticity or hardness of soft tissue, and, through digitization, provides a clinician with an image of the size and location of nodules in the tissue. While the detection technology is currently being focused on the development of a prostate imaging system, the technology is also believed to be applicable to the detection of nodules or hardness in the breast.

The detection technology is substantially covered by three United States

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

patents: Patent No. 5,265,612 entitled "Intercavity Ultrasonic Device for Elasticity Imaging"; Patent No. 5,524,636, dated June 11, 1996 entitled "Method and Apparatus for Elasticity Imaging"; and Patent No. 5,785,663 dated July 28, 1998, entitled "Method and Device for Mechanical Imaging of Prostate."

The detection technology is owned, and primary development efforts are being conducted, by ArMed, Inc., a Delaware corporation (formerly ArMed LLC, a Delaware limited liability company). Artann Corporation, a New Jersey corporation, and an earlier owner and developer of the detection technology, transferred the detection technology to ArMed, Inc. in 1996, and in return received a license to use, develop, manufacture and market a home use breast cancer system utilizing the detection technology.

Artann Corporation entered into an "Agreement for Transfer of Patent and Proprietary Rights" dated September 5, 1995, as amended on August 29, 1996, with our former parent company, Developed Technology. We refer to that agreement as the "royalty agreement" in this section. We received our rights under the royalty agreement by assignment from Developed Technology on April 23, 2001. Armen P. Sarvazyan is the original inventor of the detection technology, is the principal shareholder of Artann Corporation, and is also a party to the royalty agreement. Sarvazyan and Artann Corporation, combined, have approximately a 9.5% equity and voting interest in ArMed, Inc., on a fully diluted basis.

The royalties which we have a right to receive under the royalty agreement are based on the gross revenues of Artann Corporation and Sarvazyan. Those gross revenues, if generated, will be obtained by Artann Corporation from (i) the sale of home use breast cancer detection systems, utilizing the detection technology, (ii) the licensing or assignment to third parties of the rights to

29

manufacture and sell breast cancer detection systems utilizing the detection technology, and (iii) distributions made by ArMed, Inc. to Artann Corporation. The royalty computation is complex and not readily subject to description, and varies significantly depending upon the specific application of the detection technology.

We do not anticipate receiving any revenue under the royalty agreement for at least two years, and we do not expect any revenue we do receive to be substantial. An independent appraisal of our royalty interest under the royalty agreement was obtained in March 2001. That appraisal established a fair market value of our royalty interest at \$107,000. In accordance with Statement of Financial Accounting Standards (SFAS) No. 121, Accounting for the Impairment of Long-Lived Assets and Long-Lived Assets to be Disposed of, we determined that the carrying amount of this asset may not be recoverable and we wrote down the value of the asset to the amount of future cash flows expected to be generated by the asset. As a result of this we wrote off the \$107,000 contractual rights in 2001.

We may exchange our royalty interest for a direct equity interest in ArMed, Inc. We cannot predict whether our royalty interest will ever result in any revenues to us.

Patents and Proprietary Rights

We have six pending utility patent applications in the United States. The patent applications cover methods and compositions for reducing side effects in chemotherapeutic formulations, and improving efficacy and reducing toxicity of chemotherapeutic agents. Two of our utility patents are filed worldwide under the Patent Cooperation Treaty. (In order to retain the benefit of a PCT

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

application, national applications must be filed before the appropriate deadlines.)

We intend to file additional patent applications when appropriate, with respect to improvements in our core technology and to specific products and processes that we develop. There can be no assurance that any patents will issue from any present or future applications or, if patents do issue, that such patents will be issued on a timely basis or that claims allowed on issued patents will be sufficient to protect our technology. Our intellectual property is subject to other risks, including potential patent challenges and possible lack of protection. Please see "Risk Factors That May Affect Results -- Our competitive position depends on protection of our intellectual property" below, for additional discussion of risks related to intellectual property.

We filed with the U.S. Patent and Trademark Office (PTO) applications to register the following trademarks/service marks: ADVANCING DRUGS THROUGH GLYCOSCIENCE; GLYCO-UPGRADE; PRO-PHARMACEUTICALS, INC.; DAVANAT; UCLT and UNIVERSAL CARBOHYDRATE LINKER TECHNOLOGY. The PTO generally issues an office action several months after an application is filed which reports on its initial determination of whether a mark is registrable under the federal trademark statute. In February 2002, the PTO issued Notices of Allowance for two of these marks, ADVANCING DRUGS THROUGH GLYCOSCIENCE, and GLYCO-UPGRADE. In order to obtain registrations, we must file evidence of use by August 2002, or we must file an for an extension of time to provide evidence of use. In January 2002, the PTO informed us that the mark PRO-PHARMACEUTICALS, INC. has been approved for publication. Unless an opposition to registration is timely filed, the PTO will issue a Notice of Allowance for this mark.

Research

We anticipate that our focus will be on design and analysis of carbohydrate-based drug enhancement systems. We do not anticipate building in-house research or development facilities, or

30

hiring staff to conduct those activities. As we have done to date, we will have our pre-clinical testing conducted by outside laboratories.

Our early stage research was conducted by Toxikon Corporation, a comprehensive compliance FDA-registered service testing laboratory in Bedford, Massachusetts, that is not affiliated with Pro-Pharmaceuticals. Toxikon's laboratory is ISO-9001 certified and EN-45001 approved, meaning that it complies with quality management standards as established by the International Organization for Standardization and other international organizations. Redfield Laboratories, Inc., based in Redfield, Arkansas, is licensed by the U.S. Department of Agriculture to conduct research in laboratory animals. Testing conditions at Redfield Laboratories are in compliance with the federal Animal Welfare Act. Redfield Laboratories is not affiliated with Pro-Pharmaceuticals.

Our current research on toxicity and efficacy of several chemotherapy drugs both alone and in combinations with our mannans on cancer-carrying animals is being conducted by Southern Research Institute in Birmingham, Alabama. Southern Research Institute is an independent, not-for-profit contract research organization that is not affiliated with our company.

If we develop products eligible for clinical trials, we will contract with an independent clinical research organization to design the trial protocols and arrange for and monitor the clinical trials. We also intend to rely on academic institutions or clinical research organizations to conduct, supervise or monitor

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

some or all aspects of clinical trials involving our products. In addition, certain clinical trials for our products may be conducted by government-sponsored agencies and consequently will be dependent on governmental participation and funding. Our dependence on third-party researchers will involve risks including lessened control over the timing and other aspects of any clinical trials, since we will not be conducting them on our own. Please see "Risk Factors -- We have no experience in clinical trials," above, for additional discussion of risks related to our research.

We do not intend to manufacture our products. We anticipate that any products we develop will be manufactured by subcontractors. Please see "Risk Factors -- We will depend on third parties to manufacture and market our products," above, for additional discussion of risks related to contract manufacturing.

Manufacturing and Marketing

We are a development company and do not have, or intend to obtain, internal facilities for the manufacture of any of our products for clinical or commercial production. In order to have our products manufactured, we will initially need to develop relationships with third-party manufacturing resources, enter into collaborative arrangements with other parties that have established manufacturing capabilities or elect to have other third parties manufacture our products on a contract basis. Later we would propose to have our products manufactured and marketed pursuant to licensing agreements as discussed below.

31

We also have no marketing infrastructure, and we do not intend to develop a sales and marketing staff to commercialize pharmaceutical products. If we develop products eligible for commercial sale, we will need to rely on third parties such as licensees, collaborators, joint venture partners or independent distributors to market and sell those products. Our dependence on third-party manufacturers and marketers will involve risks relating to our lessened control, and other risks including those discussed in "Risk Factors -- We will depend on third parties to manufacture and market our products," above.

We currently envision having our manufacturing and marketing operations conducted pursuant to license agreements that we would negotiate with pharmaceutical companies with respect to manufacturing and marketing of their "upgraded" drugs. While we presently contemplate offering the rights to manufacture and market an "upgraded" drug to the original pharmaceutical company that developed the drug, we will evaluate other manufacturing and marketing arrangements as well.

Competition

We expect to encounter significant competition for the principal drug delivery systems we plan to develop. Companies that complete clinical trials, obtain required regulatory approvals and commence commercial sales of their products before their competitors may achieve a significant competitive advantage. Accordingly, the relative speed with which we and any future collaborators can develop products, complete preclinical testing and clinical trials and approval processes, and supply commercial quantities of the products to the market are expected to be important competitive factors. A number of biotechnology and pharmaceutical companies are developing new drug delivery systems for the treatment of the same diseases being targeted by us. In some instances, such products have already entered late-stage clinical trials or received FDA approval. Significant levels of research in biotechnology, medicinal chemistry and pharmacology occur in academic institutions,

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

governmental agencies and other public and private research institutions. These entities have become increasingly active in seeking patent protection and licensing revenues for their research results. They also compete with us in recruiting and retaining skilled scientific talent. Please see "Risk Factors -- We face intense competition in the biotechnology and pharmaceutical industries," above, for additional discussion related to our current and potential competition.

Our potential competition includes other companies developing drug delivery systems based on carbohydrates, as well as companies developing drug delivery systems based on other polymers. The principal competitors in the polymer area are Cell Therapeutics, Access Pharmaceuticals, Daichi, Enzon and Pharmacia which are developing alternate drugs in combination with polymers. We believe we are the only company conducting research on mannan-based drug delivery systems.

In addition, we face competition with technologies other than polymer-based delivery technologies. We believe that the principal current competitors to polymer-based targeting technology fall into two categories: monoclonal antibodies and liposomes. A number of companies are developing or may in the future engage in the development of products competitive with our drug delivery system. Several companies are working on targeted monoclonal antibody therapy including Bristol-Myers Squibb, Centocor, GlaxoSmithKline, Imclone and Xoma. Currently, liposomal formulations being developed by Nexstar (acquired by Gilead Sciences), The Liposome Company (acquired by Elan Corporation) and Sequus Pharmaceuticals (acquired by Alza Corporation), are the major competing intravenous drug delivery formulations which deliver similar drug substances. A number of companies are developing or evaluating enhanced drug delivery systems. We expect that technological developments will occur at a rapid rate and that competition is likely to intensify as various alternative delivery system technologies achieve similar if not identical advantages.

We believe that our ability to compete successfully will be based on our ability to create and maintain scientifically advanced technology, develop proprietary products, attract and retain scientific personnel, obtain patent or other protection for our products, obtain required regulatory approvals and manufacture and successfully market our products either alone or through outside parties.

32

Government Regulation

The research, development, testing, manufacture, labeling, promotion, advertising, distribution, and marketing, among other things, of our products are extensively regulated by governmental authorities in the United States and other countries. In the United States, the Food and Drug Administration (FDA) regulates drugs under the Federal Food, Drug, and Cosmetic Act and its implementing regulations. Failure to comply with the applicable U.S. requirements may subject us to administrative or judicial sanctions, such as FDA refusal to approve pending new drug applications, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, and/or criminal prosecution. Please see "Risk Factors -- We will need regulatory approvals to commercialize our products," above, for additional discussion of risks related to regulatory compliance.

Drug Approval Process

No drug may be marketed in the U.S. until the drug has received FDA approval. We have not yet submitted an application for approval for any of our product candidates. The steps required before a drug may be marketed in the U.S.

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

include:

- o preclinical laboratory tests, animal studies, and formulation studies
- o submission to the FDA of an investigational new drug application, or IND, for human clinical testing, which must become effective before human clinical trials may begin
- o adequate and well-controlled human clinical trials to establish the safety and efficacy of the drug for each indication
- o submission to the FDA of a New Drug Application, or NDA
- o satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with current Good Manufacturing Procedures established by the FDA ("cGMP") and
- o FDA review and approval of the NDA.

Preclinical tests include laboratory evaluation of product chemistry, toxicity, and formulation, as well as animal studies. The results of the preclinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND, which must become effective before human clinical trials may begin. An IND will automatically become effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions about issues such as the conduct of the trials as outlined in the IND. In such a case, the IND sponsor and the FDA must resolve any outstanding FDA concerns or questions before clinical trials can proceed. We cannot be sure that submission of an IND will result in FDA allowing clinical trials to begin.

Clinical trials involve the administration of the investigational drug to human subjects under the supervision of qualified investigators. Clinical trials are conducted under protocols detailing the objectives of the study, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each protocol must be submitted to the FDA as part of the IND.

Clinical trials typically are conducted in three sequential phases, but the phases may overlap or be combined. Each trial must be reviewed and approved by an independent Institutional Review Board before it can begin. Study subjects must sign an informed consent form before participating

33

in a clinical trial. Phase I usually involves the initial introduction of the investigational drug into people to evaluate its safety, dosage tolerance, pharmacodynamics, and, if possible, to gain an early indication of its effectiveness. Phase II usually involves trials in a limited patient population to (i) evaluate dosage tolerance and appropriate dosage; (ii) identify possible adverse effects and safety risks; and (iii) evaluate preliminarily the efficacy of the drug for specific indications. Phase III trials usually further evaluate clinical efficacy and test further for safety by using the drug in its final form in an expanded patient population. There is no assurance that these trials will be completed within a specified period of time, if at all.

Assuming successful completion of the required clinical testing, the results of the preclinical studies and of the clinical studies, together with other detailed information, including information on the manufacture and composition of the drug, are submitted to the FDA in the form of an NDA requesting approval to market the product for one or more indications. Before

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

approving an NDA, the FDA usually will inspect the facility or the facilities at which the drug is manufactured, and will not approve the product unless cGMP compliance is satisfactory. If the FDA evaluates the NDA and the manufacturing facilities as acceptable, the FDA will issue an approval letter. If the FDA evaluates the NDA submission or manufacturing facilities as not acceptable, the FDA will outline the deficiencies in the submission and often will request additional testing or information. Even if we submit the requested additional information, the FDA ultimately may decide that the NDA does not satisfy the regulatory criteria for approval. The testing and approval process requires substantial time, effort, and financial resources, and we cannot be sure that any approval will be granted on a timely basis, if at all. After approval, certain changes to the approved product, such as adding new indications, manufacturing changes, or additional labeling claims are subject to further FDA review and approval.

FDA "Fast Track" Program; Priority Review

The FDA's "fast track" program is intended to facilitate the development and expedite the review of drugs intended for the treatment of serious or life-threatening diseases and that demonstrate the potential to address unmet medical needs for such conditions. Under this program, the FDA can, for example, review portions of an NDA for a fast track product before the entire application is complete, thus potentially beginning the review process at an earlier time. We intend to seek to have some of our products designated as fast track products, with the goal of reducing review time. There can be no guarantee that the FDA will grant any of our requests for fast track designation, that any fast track designation would affect the time of review, or that the FDA will approve the NDA submitted for any of our product candidates, whether or not fast track designation is granted. Additionally, FDA approval of a fast track product can include restrictions on the product's use or distribution (such as permitting use only for specified medical procedures or limiting distribution to physicians or facilities with special training or experience), and can be conditioned on the performance of additional clinical studies after approval.

FDA procedures also provide priority review of NDAs submitted for drugs that, compared to currently marketed products, offer a significant improvement in the treatment, diagnosis, or prevention of a disease. NDAs that are granted priority review are intended to be acted upon more quickly than NDAs given standard review. The FDA's current goal is to act on 90% of priority NDAs within six months of receipt. We anticipate seeking priority review with regard to some of our product candidates. There can be no guarantee that the FDA will grant priority review status in any instance, that priority review status will affect the time of review, or that the FDA will approve the NDA submitted for any of our product candidates, whether or not priority review status is granted.

34

Post-Approval Requirements

If FDA approval of one or more of our products is obtained, we will be required to comply with a number of post-approval requirements. For example, holders of an approved NDA are required to report certain adverse reactions to the FDA, and to comply with certain requirements concerning advertising and promotional labeling for their products. Also, quality control and manufacturing procedures must continue to conform to cGMP after approval, and the FDA periodically inspects manufacturing facilities to assess compliance with cGMP. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. In addition, discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved NDA, including

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

withdrawal of the product from the market. Also, new government requirements may be established that could delay or prevent regulatory approval of our products under development.

FDA "Orphan Drug" Designation

The FDA may grant orphan drug designation to drugs intended to treat a "rare disease or condition," which generally is a disease or condition that affects fewer than 200,000 individuals in the United States. Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are publicly disclosed by the FDA. Orphan drug designation does not convey an advantage in, or shorten the duration of, the regulatory review and approval process. If a product which has an orphan drug designation subsequently receives the first FDA approval for the indication for which it has such designation, the product is entitled to orphan exclusivity, meaning that the FDA may not approve any other applications to market the same drug for the same indication, except in certain very limited circumstances, for a period of seven years. As well, orphan drugs usually receive ten years of marketing exclusivity in the E.U.

Non-United States Regulation

Before our products can be marketed outside of the United States, they are subject to regulatory approval similar to that required in the United States, although the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary widely from country to country. No action can be taken to market any product in a country until an appropriate application has been approved by the regulatory authorities in that country. The current approval process varies from country to country, and the time spent in gaining approval varies from that required for FDA approval. In certain countries, the sales price of a product must also be approved. The pricing review period often begins after market approval is granted. No assurance can be given that even if a product is approved by a regulatory authority, satisfactory prices will be approved for such product.

Environmental Regulation

Pharmaceutical research and development involves the controlled use of hazardous materials including but not limited to certain hazardous chemicals and radioactive materials. In connection with research, development and manufacturing activities, biotechnology and biopharmaceutical companies are subject to federal, state and local laws, rules, regulations and policies governing the use, generation, manufacture, storage, air emission, effluent discharge, handling and disposal of certain materials, biological specimens and wastes. Since we do not anticipate building in-house research, development or manufacturing facilities, but plan to have these activities conducted by contractors and other third parties, we do not anticipate that we will be directly affected by environmental regulations. However, our contractors and others conducting research, development or manufacturing activities for us may be required to incur significant costs to comply with

environmental and health and safety regulations in the future, and this could in turn affect our costs of doing business and might ultimately interfere with timely completion of research or manufacturing programs if those third parties are unable to comply with environmental regulatory requirements.

Employees

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

As of April 8, 2002, we have three employees, including David Platt, our President and Chief Executive Officer; Maureen Foley, our Chief Operating Officer; and an administrative assistant. All are full-time employees.

Scientific and Clinical Advisory Boards

We continue to recruit members for a Scientific Advisory Board that will include recognized scientists with expertise in the fields of carbohydrate chemistry and biochemistry, immunology, cell and molecular biology, and synthetic and medical chemistry. The Scientific Advisory Board will meet with our management on a regular basis and in smaller groups or individually from time to time on an informal basis. The members will assist us in identifying scientific and product development opportunities, reviewing with management the progress of our specific projects and recruiting and evaluating our scientific staff. We may also have a Clinical Advisory Board that will assist us from time to time on clinical matters.

The initial members of our Scientific Advisory Board are: Dr. David Platt, our President and Chief Executive Officer and a director; Dr. Anatole A. Klyosov; Dr. Dale H. Conaway, a director; Dr. Edgar Ben-Josef, a director; Dr. Henry Esber; and Dr. Mildred Christian. See "Management" for additional information about the business and educational backgrounds of these persons, other than Drs. Klyosov, Esber and Christian, whose backgrounds are as follows:

Dr. Klyosov was the Senior Vice President, Chief Scientific Officer of Pro-Pharmaceuticals (Massachusetts), our predecessor, as of its founding in July 2000. Dr. Klyosov owns 50% of MIR International, Inc., which provides consulting services regarding our research and development. See "Certain Relationships and Related Transactions -- Related Party Transactions," below. From 1996 to the present, Dr. Klyosov has served as Manager, Research and Development, for Thermo Fibergen Inc. (AMEX: TFG), a biotechnology company that develops and manufactures products including biotechnological materials and fiber-based composites. From 1990 to June 1998, Dr. Klyosov served as Professor of Biochemistry at Harvard Medical School, Center for Biochemical and Biophysical Sciences and Medicine, where he studied an enzyme involved in angiogenesis of cancer cells, glucocorticoid receptors, and biochemistry of alcohol abuse. Dr. Klyosov received a Ph.D. degree in Physical Chemistry from Moscow State University in 1972, and a D.Sc. degree in Physical Chemistry and Biochemistry from Moscow State University in 1977.

Dr. Esber is Executive Director of Business Development for Primedica Corporation, a contract research organization. Dr. Esber has served in this capacity for more than five years. Dr. Esber is a co-founder and a director of BioQuant Corporation (formerly BioSignature Diagnostics, Inc.), a developer of immunochemistry kits for diagnosis and assessment of immunological diseases. He is also a co-founder of Advanced Drug Delivery, Inc., a biotechnology company that focuses on development of drug delivery systems using co-polymers or other modifications for use in the area of cancer and other diseases. Dr. Esber serves on the Scientific Advisory Boards of several U.S. and non-U.S. biotechnology companies, including Celltek Biotechnologies, Inc., BioQuant Corporation and Delmont Laboratories. Dr. Esber received a B.S. degree in Biology from the College of William and Mary in 1961, an M.S. degree in Public Health and Parasitology from the University of North Carolina in 1963, and a Ph.D. degree in Immunology/Microbiology from West Virginia University Medical Center in 1967.

Dr. Christian is President and Chief Executive Officer of Argus International, Inc., a provider of consulting services in regulatory affairs.

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

She is also Executive Director of Research of Argus and Redfield Laboratories, both divisions of Charles River Laboratories, Inc. Since founding Argus Research Laboratories in 1979 and Argus International in 1980, she has participated at all levels in the performance, evaluation and submission of developmental ("teratology"), reproductive and general toxicology evaluations in over 1,800 studies from protocol to final report. Dr. Christian is a member of 20 professional organizations, and has served as president of each of the Teratology Society, the American College of Toxicology, and the Academy of Toxicological Sciences. She is an honorary member of the Society of Quality Assurance and founding editor of the Journal of Toxicological Sciences. She has edited or contributed to several major textbooks and is the author of over 120 papers and abstracts published in U.S. and international journals. Dr. Christian obtained her Ph.D. from Thomas Jefferson University in developmental anatomy and pharmacology.

Consulting Arrangements

We have entered into consulting arrangements directly and indirectly with an officer and certain advisors, in order to utilize their expertise at this stage of our corporate development. Each of the following agreements is terminable on thirty days' notice.

Extol International Ltd., a company controlled by James Czirr, our Executive Vice President of Business Development and a director, has agreed to provide financing and business development services. This agreement provides for a monthly payment of \$12,500 and reimbursement of expenses. Mr. Czirr owns more than 5% of our outstanding common stock.

MIR International, Inc., a company controlled by Anatole A. Klyosov, Ph.D., a member of our Scientific Advisory Board and formerly our Senior Vice President and Chief Scientific Officer, has agreed to provide consulting services regarding our research and development including design of preclinical experimental protocols, arranging preclinical experiments, performing chemical synthetic work, and preparing reports on biochemical study and clinical applications of carbohydrates. This agreement provides for a monthly payment of \$5,000 and reimbursement of expenses. Dr. Klyosov owns more than 5% of our outstanding common stock.

Eliezer Zomer, Ph.D., has agreed to provide consulting services with respect to the development of standard operations procedures for the manufacture of our medical products. This agreement provides for a monthly payment of \$2,000 and reimbursement of expenses.

Offer Binder, Ph.D., has agreed to provide management advisory services. This agreement provides for a monthly payment of \$5,000 and reimbursement of expenses. Dr. Binder owns more than 5% of our outstanding common stock.

Properties

We entered into a 5-year sublease commencing June 1, 2001 for approximately 2,830 square feet for our executive offices located at 189 Wells Avenue, Suite 200, Newton, Massachusetts 02459. The rent for the first year is \$87,730 (\$7,311 per month) and is subject to increase in subsequent years. The sublease is a so-called "triple net" lease, meaning that we must pay our proportionate share of items such as property taxes, insurance and operating costs. The sublease required us to provide a security deposit of \$48,883, of which up to \$24,442 could be in the form of a letter of credit. We paid \$26,951 in cash and provided the remainder of the security deposit in the form of a letter of credit.

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

We are currently undertaking a build-out of our office space. We estimate that the buildout will cost approximately \$80,000 before related expenditures such as office furnishings.

Subject to completion of the buildout, we believe that our currently leased facilities are suitable and adequate to meet our requirements for the near term.

Legal Proceedings

Pro-Pharmaceuticals is not a party to any litigation or legal proceedings.

MANAGEMENT

Officers and Directors

The following table sets forth information about our executive officers and directors:

Name ----	Age as of 4/8/02 -----	Position -----
David Platt, Ph.D.	48	President, Chief Executive Officer, Treasurer, Secretary and Director
Maureen Foley	60	Chief Operating Officer
James Czirr	48	Executive Vice President of Business Development and Director
Peter Hauser	61	Director
Burton C. Firtel	62	Director
Dale H. Conaway, D.V.M.	47	Director
David H. Smith	62	Director
Edgar Ben-Josef, M.D.	42	Director

Dr. Platt has served as our President, Chief Executive Officer, Treasurer, Secretary and a director since May 15, 2001. Previously, he had been President, Chief Executive Officer, Treasurer, Clerk and a director of Pro-Pharmaceuticals (Massachusetts), the Company's predecessor, since its founding in July 2000. He was Chairman of the Board, Chief Executive Officer and Secretary of SafeScience Inc. (now known as GlycoGenesys, Inc.) (NASDAQ SmallCap: GLGS) (formerly IGG International, Inc.), a biotechnology company involved in research and development of products for treating cancer and immune system diseases, from December 1992 through May 2000. Dr. Platt had been Chairman of the Board, Chief Executive Officer and Secretary of Agricultural Glycosystems, Inc., a wholly owned subsidiary of SafeScience, from its inception in June 1995 through May 2000. Agricultural Glycosystems manufactures and markets complex carbohydrate compounds for use in agriculture. He is currently a director of Integrated Pharmaceuticals, Inc. (OTCBB: INTP), a company specializing in molecular-level means of

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

increasing speed of production of enzymes for use in fermentation. Dr. Platt received a Ph.D. in Chemistry from Hebrew University in Jerusalem, Israel, in 1988, and also earned an M.S. degree in 1983 and a B.S. degree in 1978 from Hebrew University. He earned a Bachelor of Engineering degree in 1980 from Technicon in Haifa, Israel.

Ms. Foley has served as our Chief Operating Officer since October 2001 and prior to that time served as our Manager of Operations since January 2001. She has been involved in the start-up of several high tech companies, where she has been responsible for the establishment and administration of business operations including human resources and benefits, accounting and finance, marketing, product development, and project management. Her experience at start-up companies includes the following: From June 2000 to December 2000, she provided business operations services as described for eHealthDirect, Inc., a developer of medical records processing software. From October 1999 to May 2000 she provided business operations services for ArsDigita, Inc., a developer of business software and programs. From June 1996 to August 1999, Ms. Foley served with Thermo Fibergen Inc., a subsidiary of Thermo Electron Corporation, a paper waste processing developer. She is a director and Chairman of Tax/Eze, Inc. a tax preparation and financial services company, and a director of Stewart/Precision, Inc., a metal fabricator, and Ergonics, Inc., a project management firm. Ms. Foley is a graduate of The Wyndham School, Boston, Massachusetts, with a major in Mechanical Engineering.

Mr. Czirr has served as Executive Vice President of Business Development and a director since May 15, 2001. He had been a director of Pro-Pharmaceuticals (Massachusetts), our predecessor, since its founding in July 2000. He has been an independent corporate and public relations consultant for over ten years, working with various companies concerning business strategies, including issues such as organization of production, finance and capital programs, marketing strategies and incentive programs. He is a director of the following companies which are subject to the reporting requirements of the Securities Exchange Act of 1934: Metalline Mining Co. (OTCBB: MMGG), which is developing a zinc mine in Mexico; and NACO Industries Inc., which manufactures polyvinyl chloride fittings for use in agriculture, municipal and industrial applications. Mr. Czirr received a B.B.A. degree from the University of Michigan in 1976, and has completed post-graduate courses at the University of Toledo School of Business Administration, and at the College for Financial Planning.

Mr. Hauser has served as a director since May 15, 2001. He has been a director of Developed Technology Resource, Inc. (DEVT.OB), a company subject to the reporting requirements of the Securities Exchange Act of 1934, since October 1993. Since 1977, he has been employed by Equity Securities Trading Co., Inc., a Minneapolis-based brokerage firm, where he is a Registered Principal. Mr. Hauser received a B.A. from the University of Minnesota in 1965.

Mr. Firtel has served as a director since May 15, 2001. He is President of Adco Medical Supplies Incorporated, a company he founded in 1970. Adco Medical Supplies distributes disposable medical supplies to U.S. customers, mostly for hospital use. Mr. Firtel also serves as President of Plastic Fabricators Incorporated, a manufacturer of plastic burial supplies sold through distributors to customers in the funeral industry, which was acquired by Adco Medical Supplies in 1992. Mr. Firtel received a B.S. degree in Business Administration from Boston University in 1961.

Dr. Conaway has served as a director since May 15, 2001. He is currently the Deputy Regional Director and the Chief Veterinary Medical Officer for the Office of Research Compliance and Assurance, a division of the U.S. Department of Health and Human Services. From March 1998 to March 2001, he served as Manager of the Equine Drug Testing and Animal Disease Surveillance Laboratories,

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

for the Michigan Department of Agriculture. From July 1994 to March 1998, he was the Regulatory Affairs Manager for the Michigan Department of Public Health

39

Vaccine Production Division. Dr. Conaway received a D.V.M. degree from Tuskegee Institute, Tuskegee, Alabama, in 1979, and a M.S. degree in Pathology from the College of Veterinary Medicine, Michigan State University, in 1984.

Mr. Smith has served as a director since January 10, 2002. Since 1996, he has been a Founder and Managing Director of venture capital funds, as follows: Interim Advantage Fund, LLC (founded in 1996), Contra V.C., LLC (founded in 1998) and Tailwind V.C., LLC (founded in 2000). He has had significant business experience in the clinical laboratory industry. He was a co-founder, Vice President and Director of Canberra Industries, a large publicly-traded manufacturer of analytical instruments, and also of Canberra Clinical Laboratories, which was sold in 1986 to MetPath, Inc., a subsidiary of Corning, Inc. Mr. Smith received a B.A. degree in Political Science from Hampden-Sydney College in 1961.

Dr. Ben-Josef has served as a director since January 10, 2002. He is a physician specializing in radiation oncology, both as a clinician and a researcher. Since July 1995, he has served as an attending physician at the Gershenson Radiation Oncology Center, Harper Hospital, in Detroit, Michigan. Since July 2000, he has been an Associate Professor in the Department of Radiation Oncology of the Wayne State University School of Medicine. Dr. Ben-Josef received an M.D. degree from The Hebrew University - Hadassah School of Medicine in Jerusalem, Israel. He received a B.Med.Sc. degree from that institution in 1980.

None of the persons specified above share any familial relationship. Other than the persons specified above, there are currently no significant employees that we expect to make a significant contribution to our business. All of our directors serve until the next annual meeting of stockholders.

Executive Compensation

We were incorporated in January 2001 and have been inactive from that time until April 23, 2001 when we acquired certain rights to potential royalties relating to a cancer detection technology from our former parent, Developed Technology Resources, Inc. Please see "Business -- Business of Pro-Pharmaceuticals -- Cancer Detection Technology." We acquired Pro-Pharmaceuticals (Massachusetts) on May 15, 2001 by means of an exchange of stock. Pro-Pharmaceuticals (Massachusetts) was incorporated as of July 11, 2000. During the year ended December 31, 2000, none of our executive officers or directors earned any salary, bonus or other cash or non-cash compensation from Pro-Pharmaceuticals (Massachusetts) for services provided in their official capacities.

Our Board of Directors on October 18, 2001 adopted the "Pro-Pharmaceuticals, Inc. 2001 Stock Incentive Plan" which permits awards of incentive and non-qualified stock options and other forms of incentive compensation to employees and nonemployees such as directors and consultants. The Board reserved 2,000,000 of our shares of common stock for awards pursuant to the plan, all of which reserved shares could be awarded as incentive stock options. The Board agreed to recommend the plan to our stockholders for approval at the next annual or special meeting of stockholders. We have granted Burton Firtel, a director of our company, a non-qualified stock option under the plan to purchase 200,000 shares of common stock, as described below under " -- Compensation of Directors and Advisors."

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

We do not currently have an employment contract with Dr. David Platt or with any other employees. We compensate Dr. Platt at a salary of \$150,000 per year. We compensate Ms. Foley at a salary of \$75,000 per year.

40

Compensation of Directors and Advisors

We have no standard arrangement to compensate directors for their services in their capacity as directors and have no immediate plans to compensate them or the members of our Scientific Advisory Board. As of March 31, 2002, we have granted Burton Firtel, a director of our company, a non-qualified stock option under our stock incentive plan to purchase 200,000 shares of common stock at an exercise price of \$3.50 per share. The option is immediately exercisable as to 120,000 shares, and will vest as to an additional 40,000 shares on the first anniversary of the grant date, and as to the remaining 40,000 shares on the second anniversary of the grant date, provided Mr. Firtel remains a director at the applicable anniversary date.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth certain information regarding beneficial ownership of our common stock, as of April 8, 2002, by (1) each shareholder known to us to be the beneficial owner of more than 5% of our outstanding shares of common stock, (2) each of our executive officers and directors and (3) our executive officers and directors, as a group, as of April 8, 2002.

Name and Address -----	Shares of Common Stock Beneficially Owned (1) -----	Percentage of Cl	
		Before Offering -----	Af Off -----
David Platt, Ph.D 12 Appleton Circle Newton, MA 02459	4,952,747(3)	31.9%	2
James Czirr 425 Janish Drive Sandpoint, ID 83864	4,939,868(4)	31.8	2
Anatole Klyosov, Ph.D 36 Walsh Road Newton, MA 02459	1,235,467	8.0	
Offer Binder c/o Pasquale via Settembrini 14/A San Mariano 06073 Corciano (PG) Italy	1,245,878(5)	8.0	
Peter L. Hauser (6) Equity Security Investments, Inc. 701 Xenia Avenue South, Suite 100 Golden Valley, MN 55416	46,000	*	

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

Burton C. Firtel 555 Sherman Avenue Hamden, CT 06518	273,000 (7)	1.7
--	-------------	-----

41

Name and Address -----	Shares of Common Stock Beneficially Owned (1) -----	Percentage of CL ----- Before Offering -----	Af Off -----
Dale H. Conaway, D.V.M 1731 Circle Pines Fort Okemos, MI 48864	19,096 (8)	*	
Edgar Ben-Josef, M.D 12734 Vernon Avenue	--	--	
David H. Smith 82 Beachside Avenue Greens Farms, CT 06436	300,000 (9)	1.9	
All executive officers and directors as a group (7 persons)	10,530,711	66.4%	6

* Less than 1%.

(1) Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission. In computing the number of shares owned by a person and the percentage ownership of that person, shares of common stock subject to options and warrants held by that person that are currently exercisable or exercisable within 60 days of April 8, 2002, are deemed outstanding. Such shares, however, are not deemed outstanding for the purposes of computing the percentage ownership of any other person. This table has been prepared based on 15,524,410 shares of common stock outstanding as of April 8, 2002.

(2) Assumes that Pro-Pharmaceuticals sells all of the 1,428,572 shares currently being offered with this prospectus.

(3) Includes 7,379 shares, as well as 3,500 shares which may be acquired upon the exercise of an immediately exercisable share purchase warrant, all owned by Dr. Platt's wife, and as to which Dr. Platt disclaims beneficial ownership.

(4) Includes 15,000 shares owned by minor children of Mr. Czirr, as to which Mr. Czirr disclaims beneficial ownership.

(5) Includes 10,411 shares owned by Mr. Binder's wife, as to which Mr. Binder disclaims beneficial ownership.

(6) Included in selling security holders, as disclosed below in "Selling Security Holders."

(7) Includes shares which may be acquired upon the exercise of non-qualified stock option which is currently exercisable as to 120,000 shares. Also includes

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

50,000 shares which may be acquired upon the exercise of an immediately exercisable share purchase warrant.

(8) Includes 6,250 shares which may be acquired upon the exercise of an immediately exercisable share purchase warrant.

(9) Includes 150,000 shares which may be acquired upon the exercise of an immediately exercisable share purchase warrant. Mr. Smith is a member and the manager of the LLC that owns the reported securities, and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

We are not aware of any arrangements that may result in "changes in control" as that term is defined by the provisions of Item 403(c) of Regulation S-B.

42

DILUTION

At December 31, 2001, our net tangible book value was \$1,215,845 or \$0.08 per share. Net tangible book value per share is equal to our total tangible assets less our total liabilities, divided by the number of shares of common stock outstanding, which was 15,524,410 shares at December 31, 2001. For purposes of this analysis, we assume that we will sell all of the 1,428,572 shares we are currently offering, at the proposed maximum offering price per share of \$3.50. Net tangible book value dilution per share represents the difference between the amount per share paid by the purchasers of shares in our offering and the pro forma net tangible book value per share of common stock immediately after completion of this offering. After giving effect to the sale by Pro-Pharmaceuticals of 1,428,572 shares of common stock offered with this prospectus at the proposed maximum offering price of \$3.50 per share, and after deducting the estimated placement fee and offering expenses, our pro forma net tangible book value at December 31, 2001, would have been approximately \$5,670,845, or \$0.33 per share, representing an immediate increase in our pro forma net tangible book value of \$0.25 per share to existing stockholders and an immediate dilution in pro forma net tangible book value of \$3.17 per share to purchasers of common stock that we are offering with this prospectus. The following table illustrates this per share dilution:

Proposed maximum offering price per share to public		\$3.50
Net tangible book value per share at December 31, 2001	\$0.08	
Increase per share attributable to new investors	\$0.25	-----
Pro forma net tangible book value per share after offering		\$0.33 -----
Dilution per share to new investors		\$3.17 =====

The number of shares outstanding at December 31, 2001, excludes approximately 50,570 shares of common stock sold, but not yet issued, after December 31, 2001 through March 31, 2002. Also excluded are 2,078,091 shares issuable pursuant to the exercise of stock options and warrants and conversion of convertible debt. See Footnote (1) under "Capitalization," above. To the extent that outstanding options or warrants are exercised, there may be further dilution to new investors.

SELLING SECURITY HOLDERS

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

The selling security holders identified in the following table are offering for sale 1,221,890 shares of common stock. These shares were issued to shareholders of our former parent company, Developed Technology Resources, as described above under "Business -- Initial Corporate Organization, Acquisition and Merger." Forty thousand of these shares are being offered by directors, officers or principal stockholders of the company.

The selling security holders may offer their shares of common stock for sale from time to time at market prices prevailing at the time of sale or at negotiated prices, and without payment of any underwriting discounts or commissions except for usual and customary selling commissions paid to brokers or dealers.

The following table sets forth, as of April 8, 2002, the number of shares being held of record or beneficially by the selling security holders and provides by footnote reference any material relationship between the company and the selling security holder, all of which is based upon information currently available to the company.

43

Name of Selling Security Holder	Number	Percent	Beneficial Ownership of Selling Security Holder Prior to Offering (1)	Number of Shares offered hereby (2)	Beneficial Ownership of Selling Security Holder Prior to Offering (1)
Kathleen C. Anderson	183	*	183	183	
Gertrude Barbush	334	*	334	334	
Theresa S. Block	2,167	*	2,167	2,167	
Kent Bond	34	*	34	34	
Brad M. Bristol	333	*	333	333	
Michael D. Callister	67	*	67	67	
George J. Chlebecek	100	*	100	100	
Ronald G. Dorken and Cynthia J. Dorken	333	*	333	333	
Dina Drits	3,334	*	3,334	3,334	
Tanya Drits	16,667	*	16,667	16,667	
Vladimir Drits	30,000	*	30,000	30,000	

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

Russ Erkkila	167	*	167
Scott O. Fuller	167	*	167
Peter L. Hauser (3)	40,000	*	40,000
Edward J Hayward	334	*	334
LeAnn Hitchcock (4)	30,000	*	30,000
Karen Holitz	1,167	*	1,167
Norman D. Holm	3,000	*	3,000
Jennifer L. Holmers	1,167	*	1,167
Richard M. Horwood (Russell Trust)	5,667	*	5,667
William J. Howard	134	*	134
John P. Hupp (5)	247,335	1.6%	247,335
Boris Iliarski	334	*	334
Steven C. Isakson as Custodian for Evan Alden Isakson	67	*	67
Julie A. Johnson	1,167	*	1,167
Thomas Denver Kaufman	334	*	334
Kathryn M. Kubinski	1,167	*	1,167
William C. Marx and Roger W. Marx	1,334	*	1,334
Kevin P. Mc Quillan	67	*	67
Diane Meyer	833	*	833
Greg Meyer	833	*	833
Doug Morgan	34	*	34
John P. Oroark	34	*	34
Mark F. Palma and Shannon L. Palma	1,334	*	1,334
Mark Peterson	167	*	167
Loren A. Pfau and Florence A. Pfau	17	*	17
John Rhodes	5,000	*	5,000

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

Name of Selling Security Holder	Beneficial Ownership of Selling Security Holder Prior to Offering (1)		Number of Shares offered hereby (2)	Beneficial Ownership After Offering (3)
	Number	Percent		
Vernon D. Riediger	1,334	*	1,334	
Steve D. Roberts as Trustee for Steven D. Robert Trust	5,500	*	5,500	
Erlan Sagadiev	125,000	*	125,000	
Joseph J. Scancarello and Margaret Scancarello	35,000	*	35,000	
Christopher K. Schneenman	21	*	21	
Roger W. Schnobrich (6)	35,700	*	35,700	
Aaron J. Scholl as Custodian for Gordon J.	34	*	34	
Aaron J. Scholl as Custodian for Nora M.				
Joan V. Smith	134	*	134	
Dain Rauscher as Custodian for John P Smith (IRA)	166	*	166	
Theresa J. Smith	334	*	334	
Scott L. Solberg and Barb M. Solberg	100	*	100	
John Steinbergs	7,500	*	7,500	
Stephen B. Swartz as Trustee for Stephen B. Swartz (1991 Profit Sharing Plan)	6,667	*	6,667	
Leo Tutewohl (Trustee)	166	*	166	
Debra Van Der Vieren	835	*	835	
Kimberly S. Vatter	134	*	134	
Avie Wasser as Custodian for David M. Wasser	7	*	7	
Dain Rauscher as Custodian for Brenton L Wolfe (IRA)	500	*	500	
Advanced Clearing, Inc.	14,600	*	14,600	
Alpine Securities Corp.	47,850	*	47,850	
American Enterprise Investment Services	2,500	*	2,500	

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

Robert W. Baird & Co., Incorporated	202	*	202
Bear Stearns Securities Corp.	2,333	*	2,333
Brown & Company Securities Corporation	31,868	*	31,868
Charles Schwab & Co., Inc.	35,873	*	35,873
Dain Rauscher Incorporated	3	*	3
Dobbin & Co.	2,000	*	2,000
Donaldson, Lufkin and Jenrette Securities	64,136	*	64,136
E Trade Securities, Inc.	20,834	*	20,834
Edward D. Jones	534	*	534
First Clearing Corporation	4,000	*	4,000

45

Name of Selling Security Holder	Beneficial Ownership of Selling Security Holder Prior to Offering (1)		Number of Shares offered hereby (2)	Bene A —
	Number	Percent		
Fiserv Securities, Inc.	2	*	2	
Fleet Securities, Inc.	1,468	*	1,468	
GVR Co.	1	*	1	
Harris Investorline, Inc.	10,143	*	10,143	
ICLEARING CORP.	1,787	*	1,787	
Janney Montgomery Scott Inc.	350	*	350	
Lehman Brothers, Inc.	1,000	*	1,000	
Merrill Lynch, Pierce, Fenner & Smith Inc.	26,499	*	26,499	
Miller Johnson Steichen Kinnard, Inc.	20,986	*	20,986	
Millsec & Co	70,296	*	70,296	

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

Morgan Stanley Dean Witter Inc	334	*	334
National Financial Services Corporation	4,316	*	4,316
National Investor Services Corp.	12,566	*	12,566
PREFEREDTRADE, INC.	333	*	333
Prudential Securities Incorporated	6,350	*	6,350
Ragen MacKenzie Incorporated	1,010	*	1,010
Raymond James & Associates, Inc.	2,300	*	2,300
SCOTTRADE, INC.	4,167	*	4,167
Southwest Securities, Inc.	209,979	1.4%	209,979
Stifel, Nicolaus & Co Inc.	333	*	333
UBS Painewebber Inc.	2,583	*	2,583
US Bancorp Piper Jaffray Inc.	2,692	*	2,692
USAA Investment Management Company	750	*	750
Wells Fargo Bank Minnesota, N.A.	334	*	334
Total	1,221,890		

* Represents less than 1% of the outstanding shares of common stock.

- (1) Applicable percentage of ownership is based on 15,524,210 shares of common stock outstanding as of April 8, 2002, plus any securities held by such holder exercisable for or convertible into common stock within sixty (60) days after the date of this prospectus.
- (2) Assumes that all shares are sold pursuant to this offering and that no other shares of common stock are acquired or disposed of by the selling security holders prior to the termination of this offering. Because the selling security holders may sell all, some or none of their shares or may acquire or dispose of other shares of common stock, we cannot estimate the aggregate number of shares which will be sold in this offering or the number or percentage of shares of common stock that each selling security holder will own upon completion of this offering.

46

- (3) Mr. Hauser has served as a director of Pro-Pharmaceuticals since our incorporation in January 2001. He served as our Vice President from our incorporation in January 2001 until we acquired the predecessor Massachusetts corporation in May 2001. He is a director of our former parent company, Developed Technology Resource, Inc. Above list includes 6,000 shares held in IRA account for Mr. Hauser (reflected in totals for Southwest Securities, Inc.).
- (4) Ms. Hitchcock has served as Chief Executive Officer and President of our former parent company, Developed Technology Resource, Inc., since January

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

2001, and has served as Chief Financial Officer and Corporate Secretary of that company since September 1997.

- (5) Mr. Hupp served as President, Treasurer and a director of Pro-Pharmaceuticals from its incorporation in January 2001 until we acquired the predecessor Massachusetts corporation in May 2001. He is a director of our former parent company, Developed Technology Resource, Inc.
- (6) Mr. Schnobrich served as Secretary and a director of Pro-Pharmaceuticals from its incorporation in January 2001 until we acquired the predecessor Massachusetts corporation in May 2001. He is a director of our former parent company, Developed Technology Resource, Inc., and served as President of that company from June 1995 to January 2001.

We will pay all expenses in connection with the distribution of the shares of common stock being sold by the selling security holders, except for the fees and expenses of any counsel and other advisors that any selling security holders may employ to represent them in connection with the offering and any brokerage or underwriting discounts or commissions paid to broker-dealers in connection with the sale of the shares.

PLAN OF DISTRIBUTION

Of the 2,650,462 shares of Pro-Pharmaceuticals common stock offered by this prospectus, 1,428,572 shares are being sold by Pro-Pharmaceuticals on a "best efforts" basis through Atlas Capital Services, LLC, as described below. The other 1,221,890 shares may be offered and sold, from time to time, by the selling security holders identified in this prospectus. We will not receive any of the proceeds from the sale of shares by the selling security holders. We will pay the expenses of preparing this prospectus and the related registration statement.

Shares Offered by Pro-Pharmaceuticals

We are offering 1,428,572 shares of our common stock through Atlas Capital Services, LLC, on a best efforts basis, which means that Atlas Capital is not obligated to buy any of the common stock we are offering and is required only to use its reasonable best efforts to sell common stock on our behalf. Atlas Capital will offer the common stock principally to selected institutional investors. We have engaged Atlas Capital to act as our exclusive agent in connection with the shares being offered by Pro-Pharmaceuticals in this prospectus. The offering is subject to the terms and conditions set forth in a placement agent engagement agreement between us and Atlas Capital.

Atlas Capital is not obligated to and does not intend to take (or purchase) any of the shares of common stock for itself. Confirmation and definitive prospectuses will be distributed to all investors at the time of pricing, informing investors of the closing date, which will be scheduled for three business days after pricing. We will not accept any investor funds before the Registration Statement becomes effective. We may sell less than all of the shares of common stock we are offering in this prospectus. There is no required minimum number of shares that must be sold as a

condition to completion of the offering. Upon closing, (i) we will deliver to each investor the number of shares of common stock purchased by such investor in accordance with instructions previously delivered by Atlas Capital on behalf of the investors, (ii) each investor will deliver to us immediately available funds in an amount equal to the aggregate purchase price of the shares of common stock

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

being sold to that investor and (iii) we will pay Atlas Capital its fee. The offering will not continue after the closing.

We have agreed to pay Atlas Capital a placement fee of 8.5% of the proceeds of the offering (0.5% of the proceeds from sales of shares to investors that we identify) and also to issue to Atlas Capital a warrant to purchase 10% of the total number of shares sold by Pro-Pharmaceuticals to investors in this offering who are identified by Atlas Capital. The warrant will be exercisable for 5 years and the exercise price per share will be the effective per share price of investors who purchase in the offering. We have also agreed to pay Atlas Capital a non-refundable due diligence fee of \$20,000 to cover all fees of Atlas Capital and its counsel associated with this offering. We will indemnify Atlas Capital against certain liabilities, including liabilities under the Securities Act, if these liabilities arise from any negligence or misrepresentation by us.

We reserve the right to reject any order to purchase our common stock. Orders will be effective only upon acceptance by us.

Prior to this offering, there has been no public market for our common stock. The public offering price of our common stock has been determined by negotiations between Pro-Pharmaceuticals and prospective purchasers, with advice also provided by Atlas Capital. Among the factors considered in the negotiations are:

- o Prevailing market conditions;
- o Offering price of recent issuances of our common stock;
- o Market capitalizations and stages of development of other companies which we believe are comparable with our company;
- o Estimates of our business potential;
- o The present stage of our development; and
- o Other factors deemed relevant.

Shares Offered by Selling Security Holders

Pro-Pharmaceuticals will not receive any of the proceeds of the sale of the shares offered by the selling security holders.

The selling security holders have not advised us of any specific plan for distribution of the shares offered hereby, but it is anticipated that the shares will be sold from time to time by the selling security holders or by pledgees, donees, transferees or other successors in interest on a best efforts basis without an underwriter. Such sales may be made on the National Quotation Bureau's Pink Sheets, the OTC Bulletin Board, any exchange upon which our shares may trade in the future, over-the-counter, or otherwise, at prices and at terms then prevailing or at prices related to the then current market price, or in negotiated transactions. The shares may be sold by one or more of the following, without limitation:

48

- o a block trade in which the broker or dealer so engaged will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;
- o purchases by a broker or dealer for its account pursuant to this

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

prospectus;

- o ordinary brokerage transactions and transactions in which the broker solicits purchases;
- o through options, swaps or derivatives;
- o in privately negotiated transactions;
- o in transactions to cover short sales;
- o through a combination of any such methods of sale; or
- o in accordance with Rule 144 under the Securities Act, rather than pursuant to this prospectus.

The selling security holders may sell their shares directly to purchasers or may use brokers, dealers, underwriters or agents to sell their shares. Brokers or dealers engaged by the selling security holders may arrange for other brokers or dealers to participate. Brokers or dealers may receive commissions, discounts or concessions from the selling security holders, or, if any such broker-dealer acts as agent for the purchaser of shares, from the purchaser in amounts to be negotiated immediately prior to the sale. The compensation received by brokers or dealers may, but is not expected to, exceed that which is customary for the types of transactions involved. Broker-dealers may agree with a selling security holder to sell a specified number of shares at a stipulated price per share, and, to the extent the broker-dealer is unable to do so acting as agent for a selling security holder, to purchase as principal any unsold shares at the price required to fulfill the broker-dealer commitment to the selling security holder. Broker-dealers who acquire shares as principal may thereafter resell the shares from time to time in transactions, which may involve block transactions and sales to and through other broker-dealers, including transactions of the nature described above, in the over-the counter market or otherwise at prices and on terms then prevailing at the time of sale, at prices then related to the then-current market price or in negotiated transactions. In connection with resales of the shares, broker-dealers may pay to or receive from the purchasers of shares commissions as described above.

The selling security holders and any broker-dealers or agents that participate with the selling security holders in the sale of the shares may be deemed to be "underwriters" within the meaning of the Securities Act. In that event, any commissions received by broker-dealers or agents and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act.

From time to time the selling security holders may engage in short sales, short sales against the box, puts and calls and other hedging transactions in our securities, and may sell and deliver the shares in connection with such transactions or in settlement of securities loans. These transactions may be entered into with broker-dealers or other financial institutions. In addition, from time to time, a selling security holder may pledge its shares pursuant to the margin provisions of its customer agreements with its broker-dealer. Upon delivery of the shares or a default by a selling security holder, the broker-dealer or financial institution may offer and sell the pledged shares from time to time.

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

Related Party Transactions

Dr. David Platt and MIR International, Inc., were each paid \$25,000 as fees for managing the operations, compiling chemistry data and planning experiments, and conducting strategic planning for our company's predecessor during the partial year ended December 31, 2000. Dr. Platt is a founding stockholder of Pro-Pharmaceuticals (Massachusetts), and is President, Chief Executive Officer, Treasurer, Secretary and a director of our company. He owns more than 5% of our outstanding stock. Dr. Anatole Klyosov, also a founding stockholder of Pro-Pharmaceuticals (Massachusetts), owns 50% of MIR International, Inc., with the remaining 50% owned by a party unrelated to Dr. Klyosov or to us. Dr. Klyosov was Senior Vice President, Chief Scientific Officer of Pro-Pharmaceuticals (Massachusetts), our predecessor, since its founding in July 2000. Dr. Klyosov owns more than 5% of our outstanding stock.

Pro-Pharmaceuticals (Massachusetts) also issued a convertible \$7,000 note to Naomi Platt, the wife of Dr. David Platt, and issued convertible notes aggregating \$100,000 and \$12,500, respectively, to Burton Firtel and Dr. Dale Conaway, directors of our company. All of these convertible notes have been converted into shares of our common stock in accordance with their terms, pursuant to our request for early conversion. See "Plan of Operation -- Liquidity and Capital Resources" for detail as to the convertible notes and our early conversion request. The accounts payable of Pro-Pharmaceuticals (Massachusetts) include approximately \$40,000 as amounts due to our stockholders as of December 31, 2000 for operating expenses incurred.

Pro-Pharmaceuticals (Massachusetts) paid Dr. Platt, MIR International, Inc., and Offer Binder, Ph.D., \$25,000, \$50,000 and \$12,500, respectively, for services as described in the preceding paragraph that they provided to the company's predecessor during the three months ended March 31, 2001. Dr. Binder is a founding stockholder of Pro-Pharmaceuticals (Massachusetts) and currently owns more than 5% of our outstanding stock. Also during that period, Pro-Pharmaceuticals (Massachusetts) reimbursed James Czirr \$5,039 for expenses made by Mr. Czirr on that company's behalf. Mr. Czirr is also a founding stockholder of Pro-Pharmaceuticals (Massachusetts), and currently serves as our Executive Vice President of Business Development and a director. Mr. Czirr owns more than 5% of our outstanding stock.

Extol International Ltd., a company controlled by Mr. Czirr, has agreed to provide financing and business development services. This agreement provides for a monthly payment of \$12,500 and reimbursement of expenses.

MIR International, Inc., a company controlled by Dr. Klyosov as described above, has agreed to provide consulting services regarding our research and development including design of preclinical experimental protocols, arranging preclinical experiments, performing chemical synthetic work, and preparing reports on biochemical study and clinical applications of carbohydrates. This agreement provides for a monthly payment of \$5,000 and reimbursement of expenses.

Dr. Binder has agreed to provide management advisory services. This agreement provides for a monthly payment of \$5,000 and reimbursement of expenses.

Transactions with Promoters

Because we were incorporated less than five years ago, we are required to disclose any transactions we have had with "promoters" of our company. Promoters include founders of our

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

company, as well as any persons who have received 10 percent or more of our common stock in connection with the organization of our company. Our promoters are: Developed Technology Resource, Inc.; Dr. David Platt, our President and Chief Executive Officer and a director; and James Czirr, Executive Vice President of Business Development and a director.

In connection with our formation in January 2001, Developed Technology acquired 1,221,890 shares of our common stock, representing all of our common stock outstanding, for a contract right valued at \$107,000. On May 15, 2001, Developed Technology distributed its holdings of our common stock to its shareholders of record at the close of business on May 7, 2001. See "Business -- Initial Corporate Organization, Acquisition and Merger" for a discussion of the distribution and related transactions.

Each of Dr. Platt and Mr. Czirr became the owner of 10 percent or more of our common stock in connection with our acquisition of Pro-Pharmaceuticals (Massachusetts) on May 15, 2001, whereby all of the holders of Pro-Pharmaceuticals (Massachusetts) common stock, including Dr. Platt and Mr. Czirr, exchanged their Pro-Pharmaceuticals (Massachusetts) common stock for the common stock of our company. In September 2000, Pro-Pharmaceuticals (Massachusetts) had issued and sold 40,000 shares to Dr. Platt for \$4,000 in cash, and also issued and sold 40,000 shares to James Czirr for \$4,000 in cash.

DESCRIPTION OF CAPITAL STOCK

We have authorized 100,000,000 shares of common stock, \$0.001 par value per share, and 5,000,000 shares of \$0.01 par value (blank check) undesignated shares. Our common stockholders are entitled to one vote per share on all matters on which holders of common stock are entitled to vote and do not have any cumulative voting rights. This means that the holders of more than 50% of the shares of common stock voting for the election of directors can elect all of the directors if they choose to do so; and, in that event, the holders of the remaining shares of common stock would not be able to elect any person to our board of directors. Subject to the rights of holders of shares of any series of preferred stock, our common stockholders are entitled to receive such dividends as our board of directors may declare, out of legally available funds. Holders of common stock have no pre-emptive, conversion, redemption, subscription or similar rights. If Pro-Pharmaceuticals were to be liquidated, dissolved or wound up, common stockholders would be entitled to share equally in any of our assets legally available for distribution after we satisfy any outstanding debts and other liabilities as well as any amounts that might be due to holders of preferred stock, if any.

Our shares of authorized preferred stock are undesignated. Our board or directors has authority, without seeking stockholder approval, to determine the designation, preferences, rights and other privileges for any series of preferred stock that the board of directors may designate, which could include preferences on liquidation or as to dividends, voting rights including the right to vote as a separate class on certain corporate events or to elect directors designated by the holders of such series, and rights to conversion, or redemption of their shares and other matters.

We have no charter or by-law provisions that would delay, defer or prevent a change in control of Pro-Pharmaceuticals.

LEGAL MATTERS

The validity of the common stock being offered hereby will be passed upon for Pro-Pharmaceuticals by Perkins, Smith & Cohen, LLP, of Boston, Massachusetts.

EXPERTS

The financial statements for our Massachusetts predecessor corporation as of December 31, 2000 and for the period from inception (July 10, 2000) through December 31, 2000, as well as the financial statements for Pro-Pharmaceuticals, Inc. as of May 15, 2001 and for the period from inception (January 26, 2001) through May 15, 2001, included in this prospectus, have been so included in reliance on the report of Scillia Dowling & Natarelli LLC, independent accountants, given on the authority of said firm as experts in auditing and accounting.

The financial statements for Pro-Pharmaceuticals, Inc. as of December 31, 2001 and for the year then ended, and for the period from inception (July 10, 2000) to December 31, 2001, have been audited by Deloitte & Touche LLP, independent auditors, as stated in their report appearing herein (which report expresses an unqualified opinion and includes an explanatory paragraph relating to the ability of Pro-Pharmaceuticals, Inc. to continue as a going concern) and have been so included in reliance upon the report of such firm, given upon their authority as experts in auditing and accounting.

WHERE YOU CAN FIND MORE INFORMATION

We have filed a Post-Effective Amendment No. 1 to a registration statement on Form SB-2 with the SEC. This prospectus, which forms a part of that amended registration statement, does not contain all of the information included in the registration statement and the exhibits and schedules thereto as permitted by the rules and regulations of the SEC. For further information with respect to Pro-Pharmaceuticals and the shares of common stock offered hereby, please refer to the amended registration statement, including its exhibits and schedules. Statements contained in this prospectus as to the contents of any contract or other document referred to herein are not necessarily complete and, where the contract or other document is an exhibit to the amended registration statement, each such statement is qualified in all respects by the provisions of such exhibit, to which reference is hereby made. You may review a copy of the amended registration statement at the SEC's public reference room in Washington, D.C., and at the SEC's regional office in Chicago, Illinois. Please call the SEC at 1-800-SEC-0330 for further information on the operation of the public reference rooms. The amended registration statement can also be reviewed by accessing the SEC's Internet site at <http://www.sec.gov>. We are subject to the information and reporting requirements of the Securities Exchange Act and, in accordance therewith, file periodic reports, proxy statements or information statements, and other information with the SEC. These reports can also be reviewed by accessing the SEC's Internet site.

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS
ON ACCOUNTING AND FINANCIAL DISCLOSURE

The information below has been previously included in our Current Report on Form 8-K filed with the SEC on February 25, 2002, as amended and filed with the SEC as Form 8-K/A on March 8, 2002.

On February 15, 2002, we dismissed Scillia Dowling & Natarelli LLC as our independent auditors. On February 22, 2002, we engaged Deloitte & Touche LLP as our independent auditors to audit our financial statements for the fiscal year ended December 31, 2001. The decision to

dismiss Scillia Dowling & Natarelli LLC and to retain Deloitte & Touche LLP was approved by our Board of Directors and Audit Committee.

The report of Scillia Dowling & Natarelli LLC on our financial statements as of December 31, 2000, and for the period commencing July 10, 2000 (Inception) to December 31, 2000, and the review reports of Scillia Dowling & Natarelli LLC on our financial statements as of June 30, 2001 and September 30, 2001 and for the three-month and year-to-date periods, did not contain an adverse opinion or a disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope or accounting principles. We have only filed financial statements since our July 10, 2000 date of inception. On March 31, 2001, we engaged Scillia Dowling & Natarelli LLC as our independent auditors to audit our financial statements for the period commencing July 10, 2000 (Inception) to December 31, 2000. From July 10, 2000 (Inception) through February 15, 2002, there were no disagreements between Scillia Dowling & Natarelli LLC and us on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Scillia Dowling & Natarelli LLC, would have caused it to make reference to the subject matter of the disagreement in connection with its reports on our financial statements. Prior to March 31, 2001, another independent auditor had opined on our financial statements. A discussion of this auditor's resignation can be seen under "Item 2. Plan of Operation -- Business Combination and Ownership" in our Quarterly Report on Form 10-QSB for the quarterly period ended September 30, 2001, as filed with the SEC on November 14, 2001. No disagreements were reported therein.

From March 31, 2001, we did not consult with Deloitte & Touche LLP on items which involved (i) the application of accounting principles to a specified transaction, either completed or proposed, (ii) the type of audit opinion that might be rendered on our financial statements, or (iii) the subject matter of a disagreement or "reportable event."

Before we filed the Form 8-K in its original and amended versions in which the above matters were disclosed, we furnished Scillia Dowling & Natarelli LLC with a copy of the above disclosure as included in each of the original and amended forms, respectively, and requested it in each case to furnish a letter addressed to the SEC stating whether Scillia Dowling & Natarelli LLC agrees with the above statements. Copies of the letters are attached as Exhibit 16.1 and Exhibit 16.2 to the Form 8-K/A as filed with the SEC on March 8, 2002. A copy of the letter with respect to the original Form 8-K disclosure was also attached as Exhibit 16 to the Form 8-K as filed with the SEC on February 25, 2002.

FINANCIAL STATEMENTS

Index to Financial Statements

	Page

1. Independent Auditors' Report for the year ended December 31, 2001.....	F-1
2. Independent Auditors' Report with respect to the period from inception (July 10, 2000) through December 31, 2000	F-2
3. Audited Balance Sheets as of December 31, 2001 and 2000.....	F-3
4. Audited Statements of Operations for the year ended December 31, 2001	

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

and for the period from inception (July 10, 2000) to December 31, 2000, and cumulative for the period from inception to December 31, 2001.....	F-4
5. Audited Statements of Stockholders' Equity for the year ended December 31, 2001 and for the period from inception (July 10, 2000) to December 31, 2000.....	F-5
6. Audited Statements of Cash Flows for the year ended December 31, 2001 and for the period from inception (July 10, 2000) to December 31, 2000 and cumulative for the period from inception to December 31, 2001.....	F-6
7. Notes to Financial Statements for the year ended December 31, 2001 and for the period from inception (July 10, 2000) to December 31, 2000 and cumulative for the period from inception to December 31, 2001.....	F-7

INDEPENDENT AUDITORS' REPORT

To the Board of Directors and Stockholders of Pro-Pharmaceuticals, Inc.
Newton, MA

We have audited the accompanying balance sheet of Pro-Pharmaceuticals, Inc. (a development-stage company) (the "Company") as of December 31, 2001, and the related statements of operations, stockholders' equity, and cash flows for the year then ended, and for the period from inception (July 10, 2000) to December 31, 2001. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audit. The Company's financial statements as of and for the year ended December 31, 2000, and for the period from inception (July 10, 2000) through December 31, 2000, were audited by other auditors whose report, dated April 10, 2002, expressed an unqualified opinion on those statements. The financial statements for the period from inception (July 10, 2000) through December 31, 2000 reflect a cumulative net loss of \$184,582, of the total net loss of \$4,154,855. The other auditors' report has been furnished to us, and our opinion, insofar as it relates to the amounts included for such prior periods, is based solely on the report of such other auditors.

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit and the report of other auditors provide a reasonable basis for our opinion.

In our opinion, based on our audit and the report of other auditors, the 2001 financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2001, and the results of its operations and its cash flows for the year then ended, and for the period from inception (July 10, 2000) through December 31, 2001, in conformity with accounting principles generally accepted in the United States of America.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company is a development stage

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

enterprise engaged in developing technology that will reduce the toxicity and improve the efficacy of chemotherapy drugs. As discussed in Note 1 to the financial statements, the Company's recurring losses from operations and deficit accumulated during the development stage raise substantial doubt about its ability to continue as a going concern. Management's plans concerning these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/Deloitte & Touche LLP

Boston, Massachusetts

April 12, 2002

F-1

REPORT OF INDEPENDENT AUDITORS

To the Stockholders

Pro-Pharmaceuticals, Inc.

(A development stage company)

Newton, Massachusetts

We have audited the accompanying balance sheet of Pro-Pharmaceuticals, Inc. as of December 31, 2000 and the related statements of operations, changes in stockholders' deficiency and cash flows for the period from inception (July 10, 2000) through December 31, 2000. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Pro-Pharmaceuticals, Inc. at December 31, 2000 and the results of its operations and cash flows for the period from inception (July 10, 2000) through December 31, 2000, in conformity with accounting principles generally accepted in the United States of America.

/s/ Scillia Dowling & Natarelli LLC

Scillia Dowling & Natarelli LLC

Hartford, Connecticut

April 10, 2002

F-2

PRO-PHARMACEUTICALS, INC.

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

(A Development-Stage Company)

BALANCE SHEETS

DECEMBER 31, 2001 AND 2000

ASSETS

CURRENT ASSETS:

Cash and cash equivalents	\$ 1,4
Prepaid expenses and other current assets	-----

Total current assets	1,5
----------------------	-----

PROPERTY AND EQUIPMENT, Net	1
-----------------------------	---

PATENTS

DEPOSITS AND OTHER ASSETS

TOTAL ASSETS	\$ 1,7 =====
--------------	-----------------

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:

Accounts payable	\$ 2
Accrued expenses	1
Convertible notes payable (net of discount of \$0 and \$205,255 at December 31, 2001 and 2000, respectively)	1 -----

Total current liabilities	5 -----
---------------------------	------------

COMMITMENTS AND CONTINGENCIES (Note 7)

STOCKHOLDERS' EQUITY:

Common stock, \$0.001 par value; 100,000,000 shares authorized, 15,524,410 and 12,354,670 shares issued and outstanding at December 31, 2001 and 2000, respectively	5,4
Additional paid-in capital	(
Deferred compensation	(4,1
Deficit accumulated during the development stage)-----

Total stockholders' equity	1,2 -----
----------------------------	--------------

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$ 1,7 =====
--	-----------------

See notes to financial statements.

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

F-3

PRO-PHARMACEUTICALS, INC.
(A Development-Stage Company)

STATEMENTS OF OPERATIONS
YEAR ENDED DECEMBER 31, 2001, THE PERIOD FROM INCEPTION (JULY 10, 2000) TO
DECEMBER 31, 2000, AND CUMULATIVE FOR THE PERIOD FROM INCEPTION TO DECEMBER 31,
2001

	Year Ended December 31, 2001	Period Incept (July 10, to Decemb 200
OPERATING EXPENSES:		
Research and development	\$ (893,457)	\$ (10
General and administrative	(1,288,634)	(6
	-----	-----
Total operating expenses	(2,182,091)	(16
	-----	-----
INTEREST INCOME	24,917	
	-----	-----
INTEREST AND OTHER EXPENSES:		
Amortization of debt discount on convertible notes	(1,241,357)	(1
Debt conversion expense	(503,019)	
Interest expense on 10% convertible notes	(68,723)	(
	-----	-----
Total interest and other expenses	(1,813,099)	(1
	-----	-----
NET LOSS	\$ (3,970,273)	\$ (18
	=====	=====
NET LOSS PER SHARE - Basic and diluted	\$ (0.29)	\$
	=====	=====
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING -		
Basic and diluted	13,601,795	12,35
	=====	=====

See notes to financial statements.

F-4

PRO-PHARMACEUTICALS, INC.
(A Development-Stage Company)

STATEMENTS OF STOCKHOLDERS' EQUITY

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

YEAR ENDED DECEMBER 31, 2001 AND THE PERIOD FROM INCEPTION (JULY 10, 2000) TO
DECEMBER 31, 2000

	Common Stock Number of Shares	\$0.001 P Value
Issuance of founders shares	12,354,670	\$ 12,3
Beneficial conversion feature and rights to common stock embedded in convertible note	--	
Net loss	--	
	-----	-----
BALANCE, DECEMBER 31, 2000	12,354,670	12,3
Issuance of common stock and beneficial conversion feature related to convertible note	660,321	6
Issuance of common stock in connection with reverse merger with Pro-Pharmaceuticals-NV	1,221,890	1,2
Conversion of notes payable and accrued interest to common stock	598,229	5
Issuance of warrants to induce conversion of notes payable	--	
Issuance of common stock and warrants (net of issuance costs of \$16,750)	689,300	6
Deferred compensation relating to issuance of stock options	--	
Amortization of deferred compensation	--	
Net loss	--	
	-----	-----
BALANCE, DECEMBER 31, 2001	15,524,410	\$ 15,5
	=====	=====
	Deficit Accumulated During the Development Stage	Total Stockhold Equity
Issuance of founders shares	\$ (3,355)	\$ 9,
Beneficial conversion feature and rights to common stock embedded in convertible note	--	221,
Net loss	(184,582)	(184,
	-----	-----
BALANCE, DECEMBER 31, 2000	(187,937)	46,
Issuance of common stock and beneficial conversion feature related to convertible note	--	1,036,
Issuance of common stock in connection with reverse merger with Pro-Pharmaceuticals-NV	--	107,
Conversion of notes payable and accrued interest to common stock	--	1,125,
Issuance of warrants to induce conversion of notes payable	--	503,
Issuance of common stock and warrants (net of issuance costs of \$16,750)	--	2,220,
Deferred compensation relating to issuance of stock options	--	
Amortization of deferred compensation	--	147,
Net loss	(3,970,273)	(3,970,

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

BALANCE, DECEMBER 31, 2001	\$ (4,158,210)	\$ 1,215,
	=====	=====

See notes to financial statements.

F-5

PRO-PHARMACEUTICALS, INC.
(A Development-Stage Company)

STATEMENTS OF CASH FLOWS
YEAR ENDED DECEMBER 31, 2001, THE PERIOD FROM INCEPTION (JULY 10, 2000) TO
DECEMBER 31, 2000, AND CUMULATIVE FOR THE PERIOD FROM INCEPTION TO DECEMBER 31,
2001

	Year Ended December 31, 2001	Peri Inc (July to De
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net loss	\$ (3,970,273)	\$
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation	12,156	
Amortization of deferred compensation	147,317	
Amortization of debt discount on convertible notes	1,241,357	
Writeoff of intangible assets	107,000	
Debt conversion expense	503,019	
Changes in assets and liabilities:		
Prepaid and other expenses	(80,769)	
Deposits and other assets	(12,451)	
Accounts payable	157,094	
Accrued expenses	96,241	
	-----	-----
Net cash used in operating activities	(1,799,309)	
	-----	-----
CASH FLOWS FROM INVESTING ACTIVITIES:		
Purchases of property and equipment	(123,696)	
Increase in patent costs	(47,420)	
	-----	-----
Net cash used in investing activities	(171,116)	
	-----	-----
CASH FLOWS FROM FINANCING ACTIVITIES:		
Net proceeds from issuance of common stock and warrants	2,220,750	
Proceeds from convertible notes payable	1,036,102	
Proceeds from shareholder advances	--	
	-----	-----

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

Net cash provided by financing activities	3,256,852	

NET INCREASE IN CASH AND CASH EQUIVALENTS	1,286,427	
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	204,745	

CASH AND CASH EQUIVALENTS, END OF PERIOD	\$ 1,491,172	\$
	=====	=====
SUPPLEMENTAL DISCLOSURE OF CASH FLOW		
INFORMATION - Cash paid for interest	\$ --	\$
	=====	=====
NONCASH FINANCING ACTIVITIES:		
Issuance of warrants to induce conversion of notes payable	\$ 503,019	
Issuance of common stock and warrants	866,328	
Conversion of convertible notes and accrued interest to common stock	1,125,602	
Issuance of stock to acquire Pro-Pharmaceuticals -NV	107,000	

See notes to financial statements.

F-6

PRO-PHARMACEUTICALS, INC.
(A DEVELOPMENT-STAGE COMPANY)

NOTES TO FINANCIAL STATEMENTS

YEAR ENDED DECEMBER 31, 2001 AND THE PERIOD FROM INCEPTION (JULY 10, 2000) TO DECEMBER 31, 2000

1. NATURE OF BUSINESS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Business - Pro-Pharmaceuticals, Inc. (the "Company") was established in July 2000. The Company is in the development stage and is engaged in developing technology that will reduce toxicity and improve the efficacy of currently existing chemotherapy drugs by combining the drugs with a number of specific carbohydrate compounds. The carbohydrate-based drug delivery system may also have applications for drugs now used to treat other diseases and chronic health conditions.

The Company is devoting substantially all of its efforts toward product research and development and raising capital. Its product candidates are still in the research and development stage, with none yet in clinical trials. The Company is subject to a number of risks similar to those of other development-stage companies, including dependence on key individuals, uncertainty of product development and generation of revenues, dependence on outside sources of capital, risks associated with clinical trials of products, dependence on third-party collaborators for research operations, lack of experience in clinical trials, need for regulatory approval of products, risks associated with protection of intellectual property, and competition with larger, better-capitalized companies. To date, the Company has raised capital principally through the issuance of convertible notes

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

and the sale of common stock through a private placement.

The Company's financial statements have been presented on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company is in the development stage, has incurred a net loss since inception of \$4,154,855 and expects to incur additional losses in the near future. These factors raise substantial doubt about the Company's ability to continue as going concern. Successful completion of the Company's development program and, ultimately, the attainment of profitable operations is dependent upon future events, including maintaining adequate financing to fulfill its development activities and achieving a level of sales adequate to support the Company's cost structure. The Company is actively seeking additional financing to fund future operations and future significant investments in the business. However, there can be no assurance that the Company will be able to obtain financing on acceptable terms, or at all.

Reverse Merger Transaction - On May 15, 2001, Pro-Pharmaceuticals, Inc., a Nevada corporation organized in January 2001 and formerly known as DTR-Med Pharma Corp. ("Pro-Pharmaceuticals-NV"), issued 12,354,670 shares of its common stock to the stockholders of Pro-Pharmaceuticals, Inc., a Massachusetts corporation organized in July 2000 ("Pro-Pharmaceuticals-MA"), in exchange for all of the outstanding shares of the common stock of Pro-Pharmaceuticals-MA. Such exchange diluted the ownership percentage of the prior Pro-Pharmaceuticals-NV stockholders to approximately 9% and resulted in the prior stockholders of Pro-Pharmaceuticals-MA owning approximately 91% of Pro-Pharmaceuticals-NV's outstanding shares. Following the exchange of stock, Pro-Pharmaceuticals-MA, as a wholly owned subsidiary, merged with Pro-Pharmaceuticals-NV, which is the surviving corporation in the merger.

F-7

1. NATURE OF BUSINESS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Reverse Merger Transaction (Continued) - At the time of the merger, the common shares issued to the stockholders of Pro-Pharmaceuticals-NV represented a majority of the Company's common stock, enabling them to retain voting and operating control of the Company. The merger was treated as a capital transaction and was accounted for as a reverse merger in which Pro-Pharmaceuticals-MA was the accounting acquirer. The historical results presented are those of Pro-Pharmaceuticals-MA, the accounting acquirer. Information concerning common stock in 2000 has been restated on an equivalent-share basis.

Summary of Significant Accounting Policies

The accompanying financial statements reflect the application of certain accounting policies, as described in this note and elsewhere in the accompanying notes to financial statements.

Use of Estimates - The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

Cash and Cash Equivalents - The Company considers all highly liquid investments with original maturities of 90 days or less at the time of acquisition to be cash equivalents. Cash equivalents consist primarily of cash on hand and money market funds at December 31, 2001 and 2000.

Prepaid Expenses and Other Current Assets - Prepaid expenses and other current assets include deferred offering costs and amounts prepaid for rent. Deferred offering costs of \$69,208 at December 31, 2001 consist of legal and other direct costs pertaining to a private placement sale of the Company's common stock, which began on December 15, 2001. These costs have been capitalized as incurred and will be offset against proceeds from the offering when the private placement is completed.

Property and Equipment - Property and equipment, including leasehold improvements, are stated at cost, net of accumulated depreciation, and are depreciated using the straight-line method over the lesser of the estimated useful lives of the assets or the related lease term. The Company periodically evaluates the recoverability of its long-lived assets based on the expected undiscounted cash flows and recognizes impairments, if any, based on expected discounted future cash flows. The estimated useful lives are as follows:

Asset Classification	Estimated Useful Life
Computers and office equipment	Three years
Furniture and fixtures	Five years
Leasehold improvements	Life of lease

Patent Costs and Other Assets - Patent costs, which consist primarily of related legal fees, are capitalized as incurred and are amortized over the estimated useful life of the patents. As of December 31, 2001 and 2000, all patents were pending and none of the costs had been amortized. Other assets consist principally of deposits.

F-8

1. NATURE OF BUSINESS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Impairment of Long-Lived Assets - The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. As a result of this, the Company wrote off \$107,000 of contractual rights in 2001.

Research and Development Expenses - Costs associated with research and development are expensed as incurred.

Stock-Based Compensation - Statement of Financial Accounting Standards ("SFAS") No. 123, "Accounting for Stock-Based Compensation," addresses the financial accounting and reporting standards for stock or other equity-based compensation arrangements. The Company has elected to use the intrinsic-value method to account for employee stock option awards under the provisions of Accounting Principles Board ("APB") Opinion No. 25, "Accounting for Stock Issued to Employees," and provides disclosures based on the fair value method in the notes to the financial statements as permitted by SFAS No. 123 and interpretations.

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

Stock or other equity-based compensation for nonemployees must be accounted for under the fair-value method as required by SFAS No.123 and Emerging Issues Task Force No. 96-18, "Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services." Under this method, the equity-based instrument is valued at either the fair value of the consideration received or the equity instrument issued on the date of vesting. The resulting expense is recognized and charged to operations over the service period. The measurement date is generally the vesting date for nonemployees. The resulting noncash expense is recorded in the statements of operations over the vesting period of the stock.

Income Taxes - Deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the expected tax rates estimated to be in effect when such basis differences reverse. A valuation allowance is provided for the amount of deferred tax assets that, based on currently available evidence, are not expected to be realized.

Net Loss Per Share - Basic and diluted net loss per share is presented in conformity with SFAS No. 128, "Earnings Per Share," for all periods presented. In accordance with SFAS No. 128, basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period, less shares subject to repurchase. Diluted weighted-average shares are the same as basic weighted-average shares since the inclusion of 2,078,091 shares issuable pursuant to the exercise of stock options and warrants and conversion of convertible debt would have been antidilutive.

Comprehensive Income - Comprehensive income is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. The Company does not have any items of comprehensive income (loss) other than net losses as reported.

Fair Value of Financial Instruments - Financial instruments consist of cash equivalents, accounts payable, and convertible notes payable. The estimated fair value of these financial instruments approximates their carrying value due to the short-term nature of these instruments.

F-9

1. NATURE OF BUSINESS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Concentration of Credit Risk - The Company has no significant concentrations of credit risk, such as foreign exchange contracts or other hedging arrangements. Financial instruments that subject the Company to credit risk consist of cash and cash equivalents. The Company maintains its cash equivalents with well-capitalized financial institutions.

Reclassifications - Certain reclassifications have been made to the 2000 financial statements in order to conform to the 2001 presentation.

Segment Information - SFAS No. 131, "Disclosures about Segments of an Enterprise and Related Information," requires companies to report selected information about operating segments, as well as enterprise-wide disclosures about products, services, geographic areas and major customers. Operating segments are determined based on the way management organizes its business for making operating decisions and assessing performance. The Company has concluded that it operates in one operating segment.

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

Recently Issued Accounting Pronouncements - In October 2001, the FASB issued SFAS No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets," which addresses financial reporting for the impairment or disposal of long-lived assets. SFAS No. 144 supersedes SFAS No. 121 and the accounting and reporting provisions of APB Opinion No. 30 related to the disposal of a segment of a business. SFAS No. 144 will become effective in the Company's fiscal year beginning July 1, 2002. Management does not believe the adoption of SFAS No. 144 will have a significant effect on the Company's financial position or results of operations.

2. PROPERTY AND EQUIPMENT

Property and equipment consists of the following at December 31, 2001:

Computer and office equipment	\$ 56,681
Furniture and fixtures	39,746
Leasehold improvements	27,269

Total	123,696
Less accumulated depreciation	(12,156)

Property and equipment, net	\$ 111,540
	=====

3. RELATED-PARTY TRANSACTIONS

For the period from inception (July 10, 2000) through December 31, 2000, the Company paid two of its stockholders \$25,000 and \$12,500, respectively, for fees associated with research and development and the day-to-day operations of the Company.

F-10

3. RELATED-PARTY TRANSACTIONS (CONTINUED)

During 2001, the Company entered into various consulting agreements, each terminable on thirty days notice, with certain related parties as follows: (i) a corporation controlled by a person who is a stockholder, director and officer of the Company for financing and business development services in consideration for \$12,500 per month and expense reimbursement, (ii) a corporation controlled by a person who is a stockholder and officer of the Company for research and development services in consideration of \$5,000 per month and expense reimbursement, and (iii) an individual who is a stockholder of the Company for management and consultant services in consideration of \$5,000 per month and expense reimbursement. The Company had related-party consulting expenses of \$203,000 and \$77,000 for 2001 and 2000, respectively.

A stockholder and spouse of a Company officer were paid approximately \$8,000 for services during the year ended December 31, 2001. Included in convertible notes payable for the year ended December 31, 2000 was \$7,000 due to this same individual. At December 31, 2000, the Company had a payable to related parties of approximately \$40,000.

4. CONVERTIBLE NOTES

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

During 2001 and 2000 the Company issued \$1,036,102 and \$284,500 of convertible notes, respectively. The notes accrue interest at a rate of 10% per year and mature one year from their issuance dates. At the Company's discretion, the notes may be extended for a one-year period and, in consideration for the extension, holders shall receive one-quarter of one share of the Company's common stock for each whole dollar amount of principal. At any time prior to maturity, the Company may prepay, upon thirty days' notice, the amounts outstanding under the convertible notes. Within the thirty day time period, the holder may convert at the then-applicable conversion price.

At any time prior to maturity, the holder also has the right to convert the note into shares of common stock. The number of shares the holder has a right to receive upon early conversion is computed by dividing the unpaid balance of the principal and accrued and unpaid interest by 75% of the offering price of the Company's most recent equity offering. This conversion price, however, may not exceed \$2.00. At maturity, the notes are automatically converted based on dividing the principal and accrued interest by \$0.50, assuming a minimum of 10,000,000 shares outstanding.

In connection with the issuance of these convertible notes, each holder was entitled to receive one-half share of the Company's common stock for each whole dollar amount of principal. The Company has issued a total of 660,321 shares of common stock to the holders of convertible notes.

The Company has allocated \$1,248,012 of the \$1,320,602 proceeds from the issuance of the convertible debt to the common shares and the embedded beneficial conversion feature. The beneficial conversion feature was calculated at the convertible debt issuance dates based on the difference between the conversion price most beneficial to the holders and the estimated fair value of the common stock at that date. This amount, however, was limited to the proceeds received from the issuance of the convertible debt. The debt discount was initially being amortized over the one-year term of the notes, and was fully amortized upon the Company's first equity offering in June 2001, at which time the convertible debt became immediately convertible.

F-11

4. CONVERTIBLE NOTES (CONTINUED)

In August 2001, the Company offered warrants to holders of its outstanding convertible notes as an inducement to convert prior to the maturity of the notes. Holders representing \$1,125,602 of the outstanding principal and accrued interest chose to convert at a conversion price of \$2.00 per share and received 598,229 common shares and 598,229 warrants. The warrants have an exercise price of \$6.50 per share and are immediately exercisable. The warrants expire on October 1, 2005, however, the Company may, upon giving written notice, accelerate the exercise of the warrant and effect an early termination thereof in the event of either of the following: (i) the Company files a new drug application ("NDA") with the Food and Drug Administration, or (ii) the market price exceeds \$11.00 on any 10 trading days within a period of 20 consecutive trading days, as defined. In the event of acceleration, the unexercised warrants automatically terminate without payment by the Company upon the thirtieth day following the written notice. The Company valued the warrants at \$503,019 using the Black-Scholes option-pricing model, based on a deemed fair market value of the Company's common stock of \$2.28 per share, an assumed volatility of 95%, a risk-free interest rate of 3.9%, a weighted-average expected life of three years, and

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

a dividend rate of 0.0%. The value of the warrants has been recorded as a debt conversion expense.

In April 2002, the Company extended the maturity date for the \$195,000 of outstanding notes for one year. In consideration for the extension, 48,750 shares of common stock will be issued to the holders of the outstanding notes.

5. STOCKHOLDERS' EQUITY

Private Placement Shares - From May 25, 2001 through December 3, 2001, the Company sold a total of 689,300 shares of common stock for gross proceeds of \$2,237,500 through a private placement (the Private Placement) of securities. Each share sold in the Private Placement included a warrant to purchase common stock of the Company. These warrants are described below.

Warrants - As part of the Private Placement the Company issued 339,200 and 550,100 warrants to purchase common stock at \$6.50 and \$5.00 per share, respectively. All of the warrants are exercisable immediately and expire through December 2005. The Company, upon giving written notice, may accelerate the exercise of the warrants and effect an early termination thereof in the event of either of the following: (i) the Company files an NDA with the Food and Drug Administration or (ii) the market price exceeds \$11.00 and \$10.00 for warrants with exercise prices of \$6.50 and \$5.00, respectively, on any 10 trading days within a period of 20 consecutive trading days, as defined. In the event of acceleration, the unexercised warrants automatically terminate without payment by the Company upon the thirtieth day following the written notice. The Company valued the warrants at \$886,328 using the Black-Scholes option-pricing model, based on a deemed fair market value of the Company's common stock of \$2.28 per share, an assumed volatility of 95%, a risk-free interest rate of 3.9%, a weighted-average expected life of three years, and a dividend rate of 0.0%.

6. 2001 STOCK INCENTIVE PLAN

In October 2001, the Company's Board of Directors adopted the Pro-Pharmaceuticals, Inc. 2001 Stock Incentive Plan (the "Plan"), which permits awards of incentive and nonqualified stock options and other forms of incentive compensation to employees and nonemployees such as directors and consultants. The Board reserved 2,000,000 shares of common stock for issuance under the Plan.

Options granted under the Plan generally have a vesting period ranging from immediately to over a period of two years and expire 10 years from the grant date. At December 31, 2001, 1,800,000 shares were available for future grant under the Plan.

F-12

6. 2001 STOCK INCENTIVE PLAN (CONTINUED)

During 2001, the Company granted options to a nonemployee for the purchase of 200,000 shares at \$3.50 per share, thereby resulting in deferred compensation expense of \$238,892 at the time of issuance. A portion of such options vested during fiscal 2001 and the remainder will completely vest during fiscal 2002. Consulting expense is estimated based on fair value pursuant to SFAS No. 123 and EITF No. 96-18 until the final measurement date, which is the earlier of performance completion or vesting. Accordingly, the total amount of consulting expense to be recognized for stock options granted to consultants will increase or decrease over the

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

vesting/performance period based on changes in the fair value of such stock options. Total expense for the year ended December 31, 2001 related to options was \$147,317.

7. COMMITMENTS AND CONTINGENCIES

Lease Commitments - The Company leases its facility under a noncancelable operating lease that expires in May 2006. Future minimum rental payments under this operating lease as of December 31, 2001 are approximately as follows:

Year Ending December 31	
2002	\$ 98,000
2003	106,000
2004	107,000
2005	109,000
2006	46,000

Total lease payments	\$466,000 =====

Rent expense was \$0 for fiscal 2000 and approximately \$50,000 for fiscal 2001 and cumulative for the period from inception (July 10, 2000) to December 31, 2001.

In connection with the operating lease, the Company has issued a letter of credit in the amount of \$21,933 as part of the security deposit.

Contingency - GlycoGenesys, Inc. (formerly known as SafeScience, Inc.), former employer of Dr. David Platt, Chairman and Chief Executive Officer of the Company, alleged in a letter dated February 15, 2001 that Dr. Platt's activity with the Company is a violation of a noncompetition covenant he has with GlycoGenesys, Inc. Dr. Platt responded by letter dated February 19, 2001 denying the allegations and inviting a meeting to discuss them. Counsel for GlycoGenesys, Inc. indicated a willingness to resolve these matters but attempts to set up a meeting were unsuccessful. An evaluation cannot be made at this time of the likelihood of a favorable or unfavorable outcome, nor can any estimate be made as to the amount or range, if any, of potential loss. If GlycoGenesys, Inc. makes demands against the Company with respect to the allegations, the Company intends to vigorously contest all such allegations.

F-13

8. INCOME TAXES

The components of the net deferred tax asset are as follows at December 31:

	2001	2000
Operating loss carryforwards	\$ 909,000	\$ 67,000
Tax credit carryforwards	86,000	--
Depreciation temporary difference	(2,000)	--
	-----	-----
	993,000	67,000
Less valuation allowance	(993,000)	(67,000)

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

Net deferred tax asset	\$	--	\$	--
	=====		=====	

As of December 31, 2001, the Company has federal net operating loss carryforwards totaling approximately \$2,153,000 and research and development and investment tax credits of \$86,000, which expire between 2022 and 2023. Because of the Company's limited operating history and its recorded losses, management has provided, in each of the last two years, a 100% allowance against the Company's net deferred tax assets.

* * * * *

F-14

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

Item 24. Indemnification of Directors and Officers

Article V of our Articles of Incorporation provides that no director or officer of our company will be liable to us or to any of our stockholders for breach of his or her fiduciary duty as a director or officer, except for:

- o Acts or omissions by the director or officer which involve intentional misconduct, fraud or a knowing violation of law, or
- o The payment of any distribution to any of our stockholders in violation of, and as provided under, Section 78.300 of the Nevada Revised Statutes.

Our By-laws provide that we will indemnify our officers and directors to the fullest extent permitted by Section 78.7502 of the Nevada Revised Statutes, provided the officer or director acts in good faith and in a manner which he or she reasonably believes to be in or not opposed to the company's best interests, and with respect to any criminal matter, had no reasonable cause to believe that his or her conduct was unlawful. Our By-laws also provide that, to the fullest extent permitted by Section 78.751 of the Nevada Revised Statutes, we will pay the expenses of our officers and directors incurred in defending a civil or criminal action, suit or proceeding, as they are incurred and in advance of the final disposition of the matter, upon receipt of an undertaking acceptable to the Board of Directors for the repayment of such advances if it is ultimately determined by a court of competent jurisdiction that the officer or director is not entitled to be indemnified.

Subsection (1) of Section 78.7502 of the Nevada Revised Statutes empowers a corporation to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending, or completed action, suit, or proceeding, whether civil, criminal, administrative, or investigative (other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee, or agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee, or agent of another corporation, partnership, joint venture, trust, or other enterprise, against expenses (including attorneys' fees), judgments, fines, and amounts paid in settlement actually and reasonably incurred by him or her in connection with the action, suit, or proceeding if the person acted in good faith and in a manner he or she reasonably believed to be in or not opposed

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.

Subsection (2) of Section 78.7502 of the Nevada Revised Statutes empowers a corporation to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending, or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that such person acted in any of the capacities set forth in subsection (1) enumerated above, against expenses (including amounts paid in settlement and attorneys' fees) actually and reasonably incurred by him or her in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation except that no indemnification may be made in respect of any claim, issue, or matter as to which such person shall have been adjudged to be liable to the corporation, unless and only to the extent that the court in which such action or suit

55

was brought determines that in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the court shall deem proper.

Subsection (3) of Section 78.7502 of the Nevada Revised Statutes provides that to the extent a director, officer, employee, or agent of a corporation has been successful in the defense of any action, suit, or proceeding referred to in subsections (1) and (2) or in the defense of any claim, issue, or matter therein, that person shall be indemnified against expenses (including attorneys' fees) actually and reasonably incurred by him or her in connection therewith.

Section 78.751 of the Nevada Revised Statutes provides that a corporation's charter or by-laws, or an agreement made by the corporation, may provide that the expenses of officers and directors incurred in defending a civil or criminal action, suit or proceeding must be paid by the corporation as they are incurred and in advance of the final disposition of the action, suit or proceeding, upon receipt of an undertaking of the director or officer to repay the amount if it is ultimately determined by a court of competent jurisdiction that he or she is not entitled to be indemnified by the corporation. Section 78.751 also provides that indemnification and advancement of expenses authorized in or ordered by a court does not exclude any other rights to which the indemnified party may be entitled.

Section 78.752 of the Nevada Revised Statutes empowers the corporation to purchase and maintain insurance on behalf of any person acting in any of the capacities set forth in Subsection (1) of Section 78.7502 against any liability asserted against that person and liability and expenses incurred by that person in any such capacity or arising out of the person's status as such whether or not the corporation would have the power to indemnify that person against such liability and expenses.

Reference is made to Item 28 for Pro-Pharmaceuticals' undertakings in this registration statement with respect to indemnification of liabilities arising under the Securities Act of 1933, as amended.

Item 25. Other Expenses of Issuance and Distribution.

The following is a list of the expenses, other than the placement fees, to be incurred by the Registrant in connection with the preparation and filing of this Registration Statement. All amounts shown are estimates except for the SEC

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

registration fee. The Registrant will pay all expenses in connection with the distribution of the shares of common stock being sold by the selling security holders, except for the fees and expenses of any counsel and other advisors that any selling security holders may employ to represent them in connection with the offering and any brokerage or underwriting discounts or commissions paid to broker-dealers in connection with the sale of the shares.

SEC Registration Fee.....	\$ 2,811
Printing and Engraving.....	\$ 4,500
Accountants' Fees and Expenses.....	\$ 35,000
Legal Fees and Expenses.....	\$ 50,000
Placement Agent Due Diligence Fee.....	\$ 20,000
Transfer Agent Fees and Expenses.....	\$ 2,500
Other Offering Expenses.....	\$ 5,189

Total.....	\$ 120,000
	=====

56

Item 26..Recent Sales of Unregistered Securities.

1. Commencing in December 2000 and continuing through May 2001, Pro-Pharmaceuticals (Massachusetts) issued convertible notes with an aggregate principal amount of \$1,310,602 to "accredited investors" as such term is defined in Regulation D promulgated under the Securities Act of 1933. These notes are now our corporate obligations as a result of the merger with Pro-Pharmaceuticals (Massachusetts). The notes have an interest rate of 10% per year and mature one year from their issuance dates. The number of shares the holder has a right to receive upon early conversion is computed by dividing the unpaid balance of the principal and accrued and unpaid interest by 75% of the offering price of our most recent equity offering. This conversion price, however, may not exceed \$2.00. At maturity, the notes are automatically converted based on dividing the principal and accrued interest by \$0.50, assuming a minimum of 10,000,000 shares outstanding.

We have requested that the holders of the convertible notes described above convert them, in accordance with their terms, to shares of our common stock prior to the notes' maturity dates. In order to encourage early conversion by September 7, 2001, we offered to issue each noteholder who converts a common stock purchase warrant identical to the warrant offered in our terminated private placement. In the case of a noteholder who accepts our offer, the warrant we issue would be exercisable to purchase such number of shares as is equal to the number of shares of our common stock that the holder receives as of the conversion of the note. In response to our offer, holders of an aggregate of \$1,125,602 of principal and accrued interest of the convertible notes have requested conversion of their notes.

Regardless of whether a noteholder accepted our early conversion offer or later decides to convert each of our noteholders is entitled to receive, as "additional consideration" for originally purchasing the note, one-half (1/2) share of our common stock for each dollar of principal. We are completing our issuance an aggregate of 660,321 of such "additional compensation" shares. All shares of common stock issued upon conversion of the notes are "restricted securities" as defined in Rule 144 under the Securities Act.

In April 2002, we extended the maturity date for the \$195,000 of outstanding notes for one year. In consideration for the extension, 48,750 shares of common stock will be issued to the holders of the outstanding notes.

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

In issuing the notes, Pro-Pharmaceuticals (Massachusetts) relied upon the exemption provided by Rule 506 under Section 4(2) of the Securities Act of 1933.

2. In May 2001, we began a private placement of securities exempt from registration pursuant to Rule 506 of Regulation D under the Securities Act of 1933 in order to raise \$5,145,000 to cover our expenditures. We abandoned this private placement as of December 3, 2001, and terminated all offering activity on or before that date. Purchasers under the private placement had to qualify as "accredited investors" as such term is defined in Regulation D. The offered securities comprised up to 1,470,000 units, offered at \$3.50 each, of one share of our common stock and one 4-year warrant exercisable at \$6.50 to purchase one share of our common stock. We sold 689,300 units as of the date we abandoned the offering. The warrant is subject, following written notice, to acceleration if either (i) we file a New Drug Application with the FDA, or (ii) our stock is listed on an exchange and its closing price exceeds \$11.00 on any 10 trading days within a period of 20 consecutive trading days or, if our stock is quoted on the NASDAQ National Market System or Small Cap Market, or over-the-counter, and the average of the closing bid and asked prices thereon exceeds \$11.00 on any 10 trading days within a period of 20 consecutive trading days.

57

In connection with agreements with three investors in this offering who were each willing to invest a substantial amount of funds, we sold units at \$3.00 each, as follows: 133,400 of the units for a total of \$400,200; 66,700 units for a total of \$200,100; and 150,000 units for a total of \$450,000. We reduced each investor's warrant exercise price to \$5.00, and changed the warrant acceleration provision to lower the 10-day closing price threshold to \$10.00. We also granted the earliest of these investors an option to purchase an additional 200,000 units on the same terms as that investor's current purchase. The option is exercisable at any time until 30 days after we notify the investor of our receipt of notice that an investigational new drug application filed by us with the FDA has become effective for any one of our compounds.

As of the termination of this offering in December 2001, we had received proceeds of \$2,237,500 from the sale of the securities offered in this private placement. Such purchases will result in our issuing 689,300 shares of our common stock and warrants to purchase 889,300 shares of our common stock.

Item 27. Exhibits.

Exhibit Number -----	Description of Document -----
3.1	Articles of Incorporation of the Registrant, dated January 26, 2001
3.2	Amended and Restated By-laws of the Registrant
5	Opinion of Perkins, Smith & Cohen, LLP (including the consent of such firm) regarding the legality of the securities being offered
10.1	Assignment and Assumption Agreement, dated April 23, 2001, by and between Developed Technology Resource, Inc. and DTR-Med Pharma Corp.
10.2	Stock Exchange Agreement, dated April 25, 2001, by and among Developed Technology Resource, Inc., DTR-Med Pharma Corp., Pro-Pharmaceuticals, Inc. (Massachusetts) and the Shareholders (as defined therein)

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

10.3	Pro-Pharmaceuticals, Inc. 2001 Stock Incentive Plan
16	Letter from Scillia Dowling & Natarelli LLC to the Commission, dated February 25, 2002, concerning change in certifying accountant
21	Subsidiaries of the Registrant
23.1	Consent of Perkins, Smith & Cohen, LLP (included as part of Exhibit 5 hereto)
23.2	Consent of Scillia Dowling & Natarelli LLC, independent auditors
23.3	Consent of Deloitte & Touche LLP, independent auditors
24.1	Power of Attorney of Edgar Ben-Josef, M.D.

58

Exhibit Number	Description of Document
-----	-----

24.2	Power of Attorney of David H. Smith
------	-------------------------------------

* Incorporated by reference to the Registrant's Registration Statement on Form 10-SB, as filed with the Commission on June 13, 2001.

** Incorporated by reference to the Registrant's Quarterly Report on Form 10-QSB for the period ended September 30, 2001, as filed with the Commission on November 14, 2001.

*** Incorporated by reference to the Registrant's Current Report on Form 8-K as filed with the Commission on February 25, 2002.

Item 28. Undertakings.

The undersigned Registrant hereby undertakes:

1. To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement to: (i) include any prospectus required by Section 10(a)(3) of the Securities Act of 1933, as amended (the "Securities Act"); (ii) reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement; and (iii) include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

2. For the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

3. To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

4. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

5. (a) For the purpose of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed under Rule 424(b)(1), or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time the Commission declared it effective.

59

(b) For the purpose of determining any liability under the Securities Act, each such post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

60

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Post-Effective Amendment No. 1 to the Registration Statement to be signed on its behalf by the undersigned thereunto duly authorized, in Newton, Massachusetts on April 12, 2002.

PRO-PHARMACEUTICALS, INC.
Registrant

By: /s/ David Platt

Name: David Platt, Ph.D.
Title: President

Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment No. 1 to the Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

Signature -----	Title -----	Date ----
/s/ David Platt ----- David Platt, Ph.D.	President, Chief Executive Officer, Treasurer, Secretary and Director (Principal Executive, Financial and Accounting Officer)	April 12, 2002
* ----- James C. Czirr	Executive Vice President of Business Development and Director	April 12, 2002
* ----- Peter L. Hauser	Director	April 12, 2002
* ----- Burton C. Firtel	Director	April 12, 2002
* ----- Dale H. Conaway, D.V.M.	Director	April 12, 2002
* ----- David H. Smith	Director	April 22, 2002
* ----- Edgar Ben-Josef, M.D.	Director	April 19, 2002

* By David Platt,
attorney-in-fact

Exhibit Number -----	Description of Document -----
3.1	Articles of Incorporation of the Registrant, dated January 26, 2001
3.2	Amended and Restated By-laws of the Registrant
5	Opinion of Perkins, Smith & Cohen, LLP (including the consent of such firm) regarding the legality of the securities being offered
10.1	Assignment and Assumption Agreement, dated April 23, 2001, by and between Developed Technology Resource, Inc. and DTR-Med Pharma Corp.
10.2	Stock Exchange Agreement, dated April 25, 2001, by and among Developed Technology Resource, Inc., DTR-Med Pharma Corp., Pro-Pharmaceuticals, Inc. (Massachusetts) and the Shareholders (as defined therein)
10.3	Pro-Pharmaceuticals, Inc. 2001 Stock Incentive Plan

Edgar Filing: PRO PHARMACEUTICALS INC - Form POS AM

- 16 Letter from Scillia Dowling & Natarelli LLC to the Commission, dated February 25, 2002, concerning change in certifying accountant
- 21 Subsidiaries of the Registrant
- 23.1 Consent of Perkins, Smith & Cohen, LLP (included as part of Exhibit 5 hereto)
- 23.2 Consent of Scillia Dowling & Natarelli LLC, independent auditors
- 23.3 Consent of Deloitte & Touche LLP, independent auditors
- 24.1 Power of Attorney of Edgar Ben-Josef, M.D.
- 24.2 Power of Attorney of David H. Smith
- * Incorporated by reference to the Registrant's Registration Statement on Form 10-SB, as filed with the Commission on June 13, 2001.
- ** Incorporated by reference to the Registrant's Quarterly Report on Form 10-QSB for the period ended September 30, 2001, as filed with the Commission on November 14, 2001.
- *** Incorporated by reference to the Registrant's Current Report on Form 8-K as filed with the Commission on February 25, 2002.